{ "generated_at": "2026-05-14", "hardcode_disclosure": [ { "item": "Topic query", "reason": "MVP locks a single demo topic so changes in evidence state are auditable.", "status": "static" }, { "item": "Trial and publication records", "reason": "Generated from ClinicalTrials.gov and OpenAlex JSON payloads.", "status": "dynamic source-derived" }, { "item": "Clinical effect estimates", "reason": "No pooled effect is generated until source-backed effect extraction is connected.", "status": "not inferred" } ], "publications": [ { "cited_by_count": 422, "doi": "https://doi.org/10.1093/eurheartj/ehw132", "id": "https://openalex.org/W2344743510", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://academic.oup.com/eurheartj/article-pdf/37/27/2105/24121279/ehw132.pdf", "publication_date": "2016-04-29", "publication_year": 2016, "source": "European Heart Journal", "title": "A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease" }, { "cited_by_count": 2567, "doi": "https://doi.org/10.1056/nejmoa2025845", "id": "https://openalex.org/W3094429645", "is_oa": true, "oa_status": "bronze", "oa_url": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845?articleTools=true", "publication_date": "2020-10-23", "publication_year": 2020, "source": "New England Journal of Medicine", "title": "Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes" }, { "cited_by_count": 251, "doi": "https://doi.org/10.1161/circulationaha.121.057983", "id": "https://openalex.org/W3212342864", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.057983", "publication_date": "2021-11-13", "publication_year": 2021, "source": "Circulation", "title": "Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial" }, { "cited_by_count": 1129, "doi": "https://doi.org/10.1093/eurheartj/ehab777", "id": "https://openalex.org/W4206077470", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://academic.oup.com/eurheartj/article-pdf/43/6/474/42497012/ehab777.pdf", "publication_date": "2021-11-01", "publication_year": 2021, "source": "European Heart Journal", "title": "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis" }, { "cited_by_count": 1522, "doi": "https://doi.org/10.1056/nejmoa2110956", "id": "https://openalex.org/W3194763937", "is_oa": true, "oa_status": "green", "oa_url": "https://curis.ku.dk/ws/files/290115527/Cardiovascular_Events_with_Finerenone.pdf", "publication_date": "2021-08-28", "publication_year": 2021, "source": "New England Journal of Medicine", "title": "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes" }, { "cited_by_count": 110, "doi": "https://doi.org/10.1038/s41591-024-03264-4", "id": "https://openalex.org/W4402101440", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://www.nature.com/articles/s41591-024-03264-4.pdf", "publication_date": "2024-09-01", "publication_year": 2024, "source": "Nature Medicine", "title": "Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes" }, { "cited_by_count": 69, "doi": "https://doi.org/10.1016/j.jchf.2022.07.013", "id": "https://openalex.org/W4304759481", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://doi.org/10.1016/j.jchf.2022.07.013", "publication_date": "2022-10-12", "publication_year": 2022, "source": "JACC Heart Failure", "title": "Finerenone and Heart\u00a0Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes" }, { "cited_by_count": 90, "doi": "https://doi.org/10.1002/ejhf.218", "id": "https://openalex.org/W1652096387", "is_oa": true, "oa_status": "green", "oa_url": "http://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218.pdf", "publication_date": "2015-02-01", "publication_year": 2015, "source": "European Journal of Heart Failure", "title": "Rationale and Design of Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure (ARTS-HF): A Randomized Study of Finerenone vs. Eplerenone in Patients who have Worsening Chronic Heart Failure with Diabetes and/or Chronic Kidney Disease" }, { "cited_by_count": 553, "doi": "https://doi.org/10.1093/eurheartj/ehaa736", "id": "https://openalex.org/W3093851112", "is_oa": true, "oa_status": "bronze", "oa_url": "https://academic.oup.com/eurheartj/article-pdf/42/2/152/35926332/ehaa736.pdf", "publication_date": "2020-09-01", "publication_year": 2020, "source": "European Heart Journal", "title": "Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine" }, { "cited_by_count": 78, "doi": "https://doi.org/10.1517/13543784.2015.1059819", "id": "https://openalex.org/W1904700712", "is_oa": false, "oa_status": "closed", "oa_url": null, "publication_date": "2015-06-20", "publication_year": 2015, "source": "Expert Opinion on Investigational Drugs", "title": "Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease" }, { "cited_by_count": 76, "doi": "https://doi.org/10.1253/circj.cj-16-0122", "id": "https://openalex.org/W2336167206", "is_oa": true, "oa_status": "diamond", "oa_url": "https://www.jstage.jst.go.jp/article/circj/80/5/80_CJ-16-0122/_pdf", "publication_date": "2016-01-01", "publication_year": 2016, "source": "Circulation Journal", "title": "A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease" }, { "cited_by_count": 75, "doi": "https://doi.org/10.1002/ejhf.2469", "id": "https://openalex.org/W4214897998", "is_oa": true, "oa_status": "hybrid", "oa_url": "https://doi.org/10.1002/ejhf.2469", "publication_date": "2022-03-03", "publication_year": 2022, "source": "European Journal of Heart Failure", "title": "Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO\u2010DKD trial" } ], "schema": "evidenceos.report.v0.1", "source_hashes": { "ctgov": "040faaf5fbe2d05bd749e73d740af673eb695336ac96d94a8c889266fadf4e16", "openalex": "a2eb75daa511a237496c29c5c057b0bea21de15dbd7e36030419e5a5c796c77e" }, "source_urls": { "ctgov": "https://clinicaltrials.gov/api/v2/studies?query.term=finerenone&format=json", "openalex": "https://api.openalex.org/works?search=finerenone+heart+failure+OR+chronic+kidney+disease" }, "summary": { "active_trials": 30, "completed_trials": 13, "completed_with_results": 5, "completed_without_results": 8, "core_trials": 79, "meta_ready": true, "new_publications_since_anchor": 1, "new_trial_updates_since_anchor": 69, "oa_publication_candidates": 11, "publication_candidates": 12, "randomized_trials": 45, "registry_references": 315, "verdict": "Update watch triggered", "verdict_detail": "New registry updates or publication candidates exist after the surveillance anchor. Effect extraction must be reviewed before any pooled estimate is changed." }, "topic": { "clinical_question": "Does new open trial or publication evidence require a living meta-analysis update for finerenone in cardiorenal or heart-failure populations?", "ctgov_query": "finerenone", "included_condition_terms": [ "heart failure", "cardiorenal", "kidney", "renal", "nephropathy", "chronic kidney disease", "diabetes" ], "minimum_meta_ready_trials": 2, "openalex_query": "finerenone heart failure OR chronic kidney disease", "slug": "finerenone-cardiorenal-watch", "source_policy": "OA-first metadata; no effect estimates are inferred from abstracts or registry text.", "surveillance_anchor": "2024-01-01", "title": "Finerenone Cardiorenal Evidence Watch" }, "trials": [ { "completion_date": "2012-07-16", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01345656", "enrollment": 457, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2022-02-10", "nct_id": "NCT01345656", "phase": "PHASE2", "primary_outcomes": [ "Change of serum potassium" ], "registry_references": [ { "citation": "Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012 Jun;14(6):668-75. doi: 10.1093/eurjhf/hfs061. Epub 2012 May 4.", "pmid": "22562554", "type": "RESULT" }, { "citation": "Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.", "pmid": "23713082", "type": "RESULT" }, { "citation": "Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12.", "pmid": "40938666", "type": "DERIVED" }, { "citation": "Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.", "pmid": "33107592", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2011-05-09", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease" }, { "completion_date": "2013-03-21", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01687920", "enrollment": 25, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2022-02-07", "nct_id": "NCT01687920", "phase": "PHASE1", "primary_outcomes": [ "Dose proportionality of BAY94-8862 exposure in plasma when given as 1.25, 2.5, 5.0, 7.5 and 10 mg IR tablets" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2012-09-17", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets" }, { "completion_date": "2014-12-09", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01807221", "enrollment": 1066, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2021-07-06", "nct_id": "NCT01807221", "phase": "PHASE2", "primary_outcomes": [ "Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90" ], "registry_references": [ { "citation": "Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29.", "pmid": "27130705", "type": "RESULT" }, { "citation": "Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.", "pmid": "33107592", "type": "RESULT" }, { "citation": "Pitt B, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.", "pmid": "25678098", "type": "RESULT" }, { "citation": "Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12.", "pmid": "40938666", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2013-06-17", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone" }, { "completion_date": "2015-02-20", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01955694", "enrollment": 72, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2021-07-16", "nct_id": "NCT01955694", "phase": "PHASE2", "primary_outcomes": [ "The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10" ], "registry_references": [ { "citation": "Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T; ARTS-HF Japan study group. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J. 2016 Apr 25;80(5):1113-22. doi: 10.1253/circj.CJ-16-0122. Epub 2016 Apr 14.", "pmid": "27074824", "type": "RESULT" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2013-11-11", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone" }, { "completion_date": "2036-03-01", "conditions": [ "Alport Syndrome", "Hereditary Kidney Disease", "Pediatric Kidney Disease", "Thin Basement Membrane Disease", "Familial Benign Hematuria" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT02378805", "enrollment": 800, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2025-03-06", "nct_id": "NCT02378805", "phase": "Not reported", "primary_outcomes": [ "age at onset of end stage kidney failure (need for renal replacement therapy)", "life-expectancy in years (age at death)", "yearly loss of estimated glomerular filtration rate (eGFR)", "time in years until doubling or tripling of urinary albumin to creatinine ratio (UACR)" ], "registry_references": [ { "citation": "Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol. 2021 Mar;36(3):711-719. doi: 10.1007/s00467-020-04819-6. Epub 2020 Nov 6.", "pmid": "33159213", "type": "BACKGROUND" }, { "citation": "Weinstock BA, Feldman DL, Fornoni A, Gross O, Kashtan CE, Lagas S, Lennon R, Miner JH, Rheault MN, Simon JF; Workshop Participants. Clinical trial recommendations for potential Alport syndrome therapies. Kidney Int. 2020 Jun;97(6):1109-1116. doi: 10.1016/j.kint.2020.02.029. Epub 2020 Apr 6.", "pmid": "32386680", "type": "BACKGROUND" }, { "citation": "Temme J, Kramer A, Jager KJ, Lange K, Peters F, Muller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisaeter AV, Hoitsma AJ, Metcalfe W, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol. 2012 Dec;7(12):1969-76. doi: 10.2215/CJN.02190312. Epub 2012 Sep 20.", "pmid": "22997344", "type": "RESULT" }, { "citation": "Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, Muller GA, Gross O. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012 Apr;81(8):779-83. doi: 10.1038/ki.2011.452. Epub 2012 Jan 11.", "pmid": "22237748", "type": "RESULT" }, { "citation": "Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dotsch J, Muller-Wiefel DE, Hoyer P; Study Group Members of the Gesellschaft fur Padiatrische Nephrologie; Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012 Mar;81(5):494-501. doi: 10.1038/ki.2011.407. Epub 2011 Dec 14.", "pmid": "22166847", "type": "RESULT" }, { "citation": "Stock J, Kuenanz J, Glonke N, Sonntag J, Frese J, Tonshoff B, Hocker B, Hoppe B, Feldkotter M, Pape L, Lerch C, Wygoda S, Weber M, Muller GA, Gross O. Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatr Nephrol. 2017 Jan;32(1):131-137. doi: 10.1007/s00467-016-3452-z. Epub 2016 Jul 11.", "pmid": "27402170", "type": "RESULT" }, { "citation": "Frese J, Kettwig M, Zappel H, Hofer J, Grone HJ, Nagel M, Sunder-Plassmann G, Kain R, Neuweiler J, Gross O. Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. Int J Mol Sci. 2019 Jan 26;20(3):519. doi: 10.3390/ijms20030519.", "pmid": "30691124", "type": "RESULT" }, { "citation": "Boeckhaus J, Hoefele J, Riedhammer KM, Nagel M, Beck BB, Choi M, Gollasch M, Bergmann C, Sonntag JE, Troesch V, Stock J, Gross O. Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrol Dial Transplant. 2022 Nov 23;37(12):2496-2504. doi: 10.1093/ndt/gfac006.", "pmid": "35022790", "type": "RESULT" }, { "citation": "Zhang Y, Bockhaus J, Wang F, Wang S, Rubel D, Gross O, Ding J. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021 Sep;36(9):2719-2730. doi: 10.1007/s00467-021-05040-9. Epub 2021 Mar 27.", "pmid": "33772369", "type": "RESULT" }, { "citation": "Boeckhaus J, Gross O. Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study. Cells. 2021 Jul 18;10(7):1815. doi: 10.3390/cells10071815.", "pmid": "34359984", "type": "RESULT" }, { "citation": "Boeckhaus J, Gale DP, Simon J, Ding J, Zhang Y, Bergmann C, Turner AN, Hall M, Sayer JA, Srivastava S, Kang HG, Cerkauskaite-Kerpauskiene A, Gillion V, Claes KJ, Krueger B, de Fallois J, Walden U, Choi M, Schueler M, Mueller RU, Todorova P, Hohenstein B, Zeisberg M, Friede T, Knebelmann B, Halbritter J, Gross O. SGLT2-Inhibition in Patients With Alport Syndrome. Kidney Int Rep. 2024 Sep 24;9(12):3490-3500. doi: 10.1016/j.ekir.2024.09.014. eCollection 2024 Dec.", "pmid": "39698346", "type": "RESULT" } ], "relevance": "core", "sponsor": "University Hospital Goettingen", "sponsor_class": "OTHER", "start_date": "1995-07", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome" }, { "completion_date": "2020-04-14", "conditions": [ "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT02540993", "enrollment": 5734, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2023-07-24", "nct_id": "NCT02540993", "phase": "PHASE3", "primary_outcomes": [ "The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR \u226540% From Baseline Over at Least 4 Weeks, or Renal Death" ], "registry_references": [ { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.", "pmid": "31655812", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "RESULT" }, { "citation": "Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.", "pmid": "33198491", "type": "RESULT" }, { "citation": "Mielke J, Strunz T, Lee J, Schloemer P; GCKD Investigators; Gallone G. An integrative framework for drug target discovery bridging clinical trial and genetic data insights. J Transl Med. 2026 Mar 13;24(1):374. doi: 10.1186/s12967-026-07806-x.", "pmid": "41827014", "type": "DERIVED" }, { "citation": "Weingold R, Filippatos G, Anker SD, Wanner C, Shafi T, Tangri N, Pitt B, Brinker M, Scott C, Roberts L, Rossing P, Inzucchi SE; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY. J Diabetes Complications. 2026 Apr;40(4):109274. doi: 10.1016/j.jdiacomp.2026.109274. Epub 2026 Jan 31.", "pmid": "41679125", "type": "DERIVED" }, { "citation": "Munoz Mendoza J, Weir MR, Anker SD, Filippatos G, Rossing P, Ahlers C, Brinker M, Fatoba ST, Horvat-Broecker A, Rohwedder K, Fornoni A; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. Clin J Am Soc Nephrol. 2026 Mar 1;21(3):414-424. doi: 10.2215/CJN.0000000932. Epub 2026 Jan 14.", "pmid": "41533467", "type": "DERIVED" }, { "citation": "Katayama S, Anker SD, Zhu D, Kim S, Wu MJ, Kawanami D, Rossing P, Ruilope LM, Ahlers C, Brinker M, Mann A, Tian Y, Yamashita S, Pitt B; FIDELIO-DKD and FIGARO-DKD Investigators. Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function. J Diabetes Complications. 2026 Jan;40(1):109213. doi: 10.1016/j.jdiacomp.2025.109213. Epub 2025 Nov 4.", "pmid": "41289823", "type": "DERIVED" }, { "citation": "Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6.", "pmid": "41196655", "type": "DERIVED" }, { "citation": "Ferreira JP, Mendonca L, Marques P, Neves JS, Zannad F, Packer M. Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes. J Am Soc Nephrol. 2026 Feb 1;37(2):390-393. doi: 10.1681/ASN.0000000877. Epub 2025 Sep 2. No abstract available.", "pmid": "40892478", "type": "DERIVED" }, { "citation": "Jongs N, Gasparyan SB, Frison L, Schloemer P, Brinker M, Little DJ, Heerspink HJL. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point. J Am Soc Nephrol. 2025 Dec 1;36(12):2421-2430. doi: 10.1681/ASN.0000000766. Epub 2025 Jun 17.", "pmid": "40526444", "type": "DERIVED" }, { "citation": "Rossing P, Birkenfeld AL, Fioretto P, McGill JB, Anker SD, Pitt B, Rohwedder K, Scalise A, Scott C, Filippatos G; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clin J Am Soc Nephrol. 2025 May 2;20(7):968-977. doi: 10.2215/CJN.0000000700.", "pmid": "40315020", "type": "DERIVED" }, { "citation": "Pitt B, Agarwal R, Anker SD, Rossing P, Ruilope L, Herzog CA, Greenberg B, Pecoits-Filho R, Lambelet M, Lawatscheck R, Scalise A, Filippatos G. Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):10-19. doi: 10.1093/ehjcvp/pvae074.", "pmid": "39380152", "type": "DERIVED" }, { "citation": "Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19;14(3):e076444. doi: 10.1136/bmjopen-2023-076444.", "pmid": "38508632", "type": "DERIVED" }, { "citation": "Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.", "pmid": "38048573", "type": "DERIVED" }, { "citation": "Flack JM, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Adler SG, Fried L, Jamerson K, Toto R, Brinker M, Farjat AE, Kolkhof P, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials. Kidney Med. 2023 Sep 28;5(12):100730. doi: 10.1016/j.xkme.2023.100730. eCollection 2023 Dec.", "pmid": "38046911", "type": "DERIVED" }, { "citation": "Heerspink HJL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpefors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 Dec 1;34(12):2025-2038. doi: 10.1681/ASN.0000000000000243. Epub 2023 Oct 24.", "pmid": "37872654", "type": "DERIVED" }, { "citation": "Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, Gonzalez F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Med. 2023 Aug 1;5(10):100704. doi: 10.1016/j.xkme.2023.100704. eCollection 2023 Oct.", "pmid": "37745646", "type": "DERIVED" }, { "citation": "Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7.", "pmid": "36927680", "type": "DERIVED" }, { "citation": "Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb.", "pmid": "36864892", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, August P, Coats AJS, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Sarafidis P, Teerlink JR, Kapelios CJ, Gebel M, Brinker M, Joseph A, Lage A, Bakris G, Agarwal R. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):183-191. doi: 10.1093/ehjcvp/pvad001.", "pmid": "36639130", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12.", "pmid": "36328655", "type": "DERIVED" }, { "citation": "Pitt B, Agarwal R, Anker SD, Ruilope LM, Rossing P, Ahlers C, Brinker M, Joseph A, Lambelet M, Lawatscheck R, Filippatos GS; FIDELIO-DKD and FIGARO-DKD Investigators. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123.", "pmid": "36287567", "type": "DERIVED" }, { "citation": "Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N, Nowack C, Bakris GL; FIDELIO-DKD Investigators. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 Dec;79(12):2685-2695. doi: 10.1161/HYPERTENSIONAHA.122.19744. Epub 2022 Oct 12.", "pmid": "36252131", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):85-93. doi: 10.1093/ehjcvp/pvac054.", "pmid": "36251465", "type": "DERIVED" }, { "citation": "Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944.", "pmid": "35061867", "type": "DERIVED" }, { "citation": "Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Wanner C, Joseph A, Scheerer MF, Scott C, Bakris GL; FIDELIO-DKD Investigators. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney Int Rep. 2021 Oct 14;7(1):36-45. doi: 10.1016/j.ekir.2021.10.008. eCollection 2022 Jan.", "pmid": "35005312", "type": "DERIVED" }, { "citation": "Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.", "pmid": "34850173", "type": "DERIVED" }, { "citation": "Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079. Epub 2021 May 17.", "pmid": "34015478", "type": "DERIVED" }, { "citation": "Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish.", "pmid": "33358451", "type": "DERIVED" }, { "citation": "Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A; FIDELIO-DKD and FIGARO-DKD Investigators. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023. doi: 10.1093/ndt/gfaa294.", "pmid": "33280027", "type": "DERIVED" }, { "citation": "Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.", "pmid": "33107592", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2015-09-17", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease" }, { "completion_date": "2021-02-02", "conditions": [ "Diabetic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT02545049", "enrollment": 7352, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2022-04-15", "nct_id": "NCT02545049", "phase": "PHASE3", "primary_outcomes": [ "The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure." ], "registry_references": [ { "citation": "Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.", "pmid": "31665733", "type": "RESULT" }, { "citation": "Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.", "pmid": "34449181", "type": "RESULT" }, { "citation": "Mielke J, Strunz T, Lee J, Schloemer P; GCKD Investigators; Gallone G. An integrative framework for drug target discovery bridging clinical trial and genetic data insights. J Transl Med. 2026 Mar 13;24(1):374. doi: 10.1186/s12967-026-07806-x.", "pmid": "41827014", "type": "DERIVED" }, { "citation": "Weingold R, Filippatos G, Anker SD, Wanner C, Shafi T, Tangri N, Pitt B, Brinker M, Scott C, Roberts L, Rossing P, Inzucchi SE; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY. J Diabetes Complications. 2026 Apr;40(4):109274. doi: 10.1016/j.jdiacomp.2026.109274. Epub 2026 Jan 31.", "pmid": "41679125", "type": "DERIVED" }, { "citation": "Munoz Mendoza J, Weir MR, Anker SD, Filippatos G, Rossing P, Ahlers C, Brinker M, Fatoba ST, Horvat-Broecker A, Rohwedder K, Fornoni A; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. Clin J Am Soc Nephrol. 2026 Mar 1;21(3):414-424. doi: 10.2215/CJN.0000000932. Epub 2026 Jan 14.", "pmid": "41533467", "type": "DERIVED" }, { "citation": "Katayama S, Anker SD, Zhu D, Kim S, Wu MJ, Kawanami D, Rossing P, Ruilope LM, Ahlers C, Brinker M, Mann A, Tian Y, Yamashita S, Pitt B; FIDELIO-DKD and FIGARO-DKD Investigators. Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function. J Diabetes Complications. 2026 Jan;40(1):109213. doi: 10.1016/j.jdiacomp.2025.109213. Epub 2025 Nov 4.", "pmid": "41289823", "type": "DERIVED" }, { "citation": "Ferreira JP, Mendonca L, Marques P, Neves JS, Zannad F, Packer M. Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes. J Am Soc Nephrol. 2026 Feb 1;37(2):390-393. doi: 10.1681/ASN.0000000877. Epub 2025 Sep 2. No abstract available.", "pmid": "40892478", "type": "DERIVED" }, { "citation": "Rossing P, Birkenfeld AL, Fioretto P, McGill JB, Anker SD, Pitt B, Rohwedder K, Scalise A, Scott C, Filippatos G; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clin J Am Soc Nephrol. 2025 May 2;20(7):968-977. doi: 10.2215/CJN.0000000700.", "pmid": "40315020", "type": "DERIVED" }, { "citation": "Singh AK, James G, Anker SD, Pitt B, Rossing P, Ruilope LM, Farjat AE, Farag YMK, Roberts L, Filippatos G; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY. JACC Adv. 2025 Feb;4(2):101524. doi: 10.1016/j.jacadv.2024.101524.", "pmid": "40021271", "type": "DERIVED" }, { "citation": "Pitt B, Agarwal R, Anker SD, Rossing P, Ruilope L, Herzog CA, Greenberg B, Pecoits-Filho R, Lambelet M, Lawatscheck R, Scalise A, Filippatos G. Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):10-19. doi: 10.1093/ehjcvp/pvae074.", "pmid": "39380152", "type": "DERIVED" }, { "citation": "Bansal S, Canziani MEF, Birne R, Anker SD, Bakris GL, Filippatos G, Rossing P, Ruilope LM, Farjat AE, Kolkhof P, Lage A, Brinker M, Pitt B. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19;14(3):e076444. doi: 10.1136/bmjopen-2023-076444.", "pmid": "38508632", "type": "DERIVED" }, { "citation": "Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5.", "pmid": "38048573", "type": "DERIVED" }, { "citation": "Flack JM, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Adler SG, Fried L, Jamerson K, Toto R, Brinker M, Farjat AE, Kolkhof P, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials. Kidney Med. 2023 Sep 28;5(12):100730. doi: 10.1016/j.xkme.2023.100730. eCollection 2023 Dec.", "pmid": "38046911", "type": "DERIVED" }, { "citation": "Rosas SE, Ruilope LM, Anker SD, Pitt B, Rossing P, Bonfanti AAC, Correa-Rotter R, Gonzalez F, Munoz CFJ, Pergola P, Umpierrez GE, Scalise A, Scott C, Lawatscheck R, Joseph A, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis. Kidney Med. 2023 Aug 1;5(10):100704. doi: 10.1016/j.xkme.2023.100704. eCollection 2023 Oct.", "pmid": "37745646", "type": "DERIVED" }, { "citation": "Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7.", "pmid": "36927680", "type": "DERIVED" }, { "citation": "Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb.", "pmid": "36864892", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, August P, Coats AJS, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Sarafidis P, Teerlink JR, Kapelios CJ, Gebel M, Brinker M, Joseph A, Lage A, Bakris G, Agarwal R. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):183-191. doi: 10.1093/ehjcvp/pvad001.", "pmid": "36639130", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12.", "pmid": "36328655", "type": "DERIVED" }, { "citation": "Pitt B, Agarwal R, Anker SD, Ruilope LM, Rossing P, Ahlers C, Brinker M, Joseph A, Lambelet M, Lawatscheck R, Filippatos GS; FIDELIO-DKD and FIGARO-DKD Investigators. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123.", "pmid": "36287567", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):85-93. doi: 10.1093/ehjcvp/pvac054.", "pmid": "36251465", "type": "DERIVED" }, { "citation": "Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13.", "pmid": "34775784", "type": "DERIVED" }, { "citation": "Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish.", "pmid": "33358451", "type": "DERIVED" }, { "citation": "Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A; FIDELIO-DKD and FIGARO-DKD Investigators. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023. doi: 10.1093/ndt/gfaa294.", "pmid": "33280027", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2015-09-17", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease" }, { "completion_date": "2024-06-14", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT04435626", "enrollment": 6016, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2025-08-26", "nct_id": "NCT04435626", "phase": "PHASE3", "primary_outcomes": [ "Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events", "Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events" ], "registry_references": [ { "citation": "Bhatt AS, Chatur S, Claggett BL, Lay-Flurrie J, Viswanathan P, Vardeny O, Kosiborod MN, Sharma K, Solomon SD, Vaduganathan M. Gamified Behavioral Science Intervention to Enhance Trial Enrollment: An Embedded Study Within the FINEARTS-HF Trial. JACC Heart Fail. 2024 Nov;12(11):1939-1941. doi: 10.1016/j.jchf.2024.05.002. Epub 2024 May 11. No abstract available.", "pmid": "38944793", "type": "RESULT" }, { "citation": "Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJV. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024 Sep 21;404(10458):1119-1131. doi: 10.1016/S0140-6736(24)01733-1. Epub 2024 Sep 1.", "pmid": "39232490", "type": "RESULT" }, { "citation": "Kondo T, Henderson AD, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, McMurray JJV. Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? J Am Coll Cardiol. 2024 Nov 26;84(22):2233-2240. doi: 10.1016/j.jacc.2024.08.033. Epub 2024 Sep 1.", "pmid": "39217560", "type": "RESULT" }, { "citation": "Ostrominski JW, Aggarwal R, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure. J Card Fail. 2024 Sep;30(9):1170-1174. doi: 10.1016/j.cardfail.2024.04.015. Epub 2024 May 11. No abstract available.", "pmid": "38740173", "type": "RESULT" }, { "citation": "Ostrominski JW, Claggett BL, Miao ZM, Mc Causland FR, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Bomfim Wirtz A, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD, Vaduganathan M. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis. J Am Coll Cardiol. 2024 Jul 9;84(2):223-228. doi: 10.1016/j.jacc.2024.05.005. Epub 2024 May 12. No abstract available.", "pmid": "38744407", "type": "RESULT" }, { "citation": "Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.", "pmid": "39225278", "type": "RESULT" }, { "citation": "Solomon SD, Ostrominski JW, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Ma CS, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang SM, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov LG, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Viswanathan P, McMurray JJV. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1334-1346. doi: 10.1002/ejhf.3266. Epub 2024 May 11.", "pmid": "38733212", "type": "RESULT" }, { "citation": "Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1324-1333. doi: 10.1002/ejhf.3253. Epub 2024 May 14.", "pmid": "38742248", "type": "RESULT" }, { "citation": "Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1.", "pmid": "39218030", "type": "RESULT" }, { "citation": "Vaduganathan M, Neuen BL, McCausland F, Jhund PS, Docherty KF, McMurray JJV, Solomon SD. Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? J Am Coll Cardiol. 2024 Nov 26;84(22):2241-2245. doi: 10.1016/j.jacc.2024.08.034. Epub 2024 Sep 1. No abstract available.", "pmid": "39217561", "type": "RESULT" }, { "citation": "Hamatani Y, Claggett BL, Desai AS, Lewis EF, Jhund PS, Lam CSP, Martinez FA, Zannad F, Pfeffer MA, McMurray JJV, Solomon SD, Vaduganathan M. Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure. J Am Coll Cardiol. 2026 Mar 16:S0735-1097(26)05744-X. doi: 10.1016/j.jacc.2026.03.026. Online ahead of print.", "pmid": "41995644", "type": "DERIVED" }, { "citation": "Lu H, Kosztin A, Claggett BL, Foa A, Pabon MA, Desai AS, Jhund PS, Henderson AD, Merkely B, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Amarante F, Saarinen R, De Sanctis Y, Glasauer A, McMurray JJV, Vaduganathan M, Solomon SD. Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2026 Mar 28:e260682. doi: 10.1001/jamacardio.2026.0682. Online ahead of print.", "pmid": "41903171", "type": "DERIVED" }, { "citation": "Chimura M, McDowell K, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Glasauer A, Goea L, Berger M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2026 Mar 28:e261049. doi: 10.1001/jamacardio.2026.1049. Online ahead of print.", "pmid": "41903165", "type": "DERIVED" }, { "citation": "Hamatani Y, Peikert A, Claggett BL, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Lay-Flurrie J, Lage A, Hofmeister L, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Eur J Heart Fail. 2026 Mar 12:xuag062. doi: 10.1093/ejhf/xuag062. Online ahead of print.", "pmid": "41817207", "type": "DERIVED" }, { "citation": "Chimura M, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lay-Flurrie J, Scalise A, Rohwedder K, Lam CSP, Senni M, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial. Eur J Heart Fail. 2026 Jan 14:xuag008. doi: 10.1093/ejhf/xuag008. Online ahead of print.", "pmid": "41771075", "type": "DERIVED" }, { "citation": "Henderson AD, Docherty KF, Talebi A, Kondo T, Petrie MC, Claggett BL, Desai AS, Vaduganathan M, Atherton JJ, Bauersachs J, Schou M, Verma S, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Brinker M, Amarante F, Rohwedder K, Lay-Flurrie J, Solomon SD, McMurray JJV, Jhund PS. A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. Eur Heart J Cardiovasc Pharmacother. 2026 Feb 16:pvag010. doi: 10.1093/ehjcvp/pvag010. Online ahead of print.", "pmid": "41697954", "type": "DERIVED" }, { "citation": "Chimura M, Henderson AD, Jhund PS, Claggett BL, Desai AS, Filippatos G, Gajos G, Brinker M, Amarante F, Lay-Flurrie J, Rohwedder K, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF. JACC Heart Fail. 2026 Feb 2:102938. doi: 10.1016/j.jchf.2026.102938. Online ahead of print.", "pmid": "41642173", "type": "DERIVED" }, { "citation": "Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. Circ Heart Fail. 2026 Feb;19(2):e013201. doi: 10.1161/CIRCHEARTFAILURE.125.013201. Epub 2026 Jan 29.", "pmid": "41608790", "type": "DERIVED" }, { "citation": "Foa A, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Henderson AD, Chatur S, Amarante F, Hofmeister L, Horvat-Broecker A, Kuhls S, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2026 Apr;14(4):102779. doi: 10.1016/j.jchf.2025.102779. Epub 2025 Dec 9.", "pmid": "41364043", "type": "DERIVED" }, { "citation": "Ostrominski JW, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Rohwedder K, Brinker M, Schloemer P, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial. Eur J Heart Fail. 2025 Dec;27(12):2788-2799. doi: 10.1002/ejhf.70034. Epub 2025 Sep 8.", "pmid": "40916719", "type": "DERIVED" }, { "citation": "Lu H, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Voors AA, Senni M, Zannad F, Pitt B, Shah SJ, Lam CSP, Scheerer MF, Scalise A, Mueller K, Berger M, Goea L, McMurray JJV, Solomon SD. Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. 2025 Oct;13(10):102590. doi: 10.1016/j.jchf.2025.102590. Epub 2025 Aug 25.", "pmid": "40857999", "type": "DERIVED" }, { "citation": "Chimura M, Jhund PS, Henderson AD, Yang M, Claggett BL, Desai AS, Rohwedder K, Lage A, Scalise A, Mueller K, Schou M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 13;10(10):979-89. doi: 10.1001/jamacardio.2025.2551. Online ahead of print.", "pmid": "40802267", "type": "DERIVED" }, { "citation": "Butt JH, Jhund PS, Henderson AD, Claggett BL, Chiang CE, Linssen GCM, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, von Lewinski D, Lay-Flurrie J, Scalise A, Rohwedder K, Desai AS, Lam CSP, Senni M, Shah SJ, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 1;10(8):829-840. doi: 10.1001/jamacardio.2025.1775.", "pmid": "40531488", "type": "DERIVED" }, { "citation": "Ferreira JP, Zannad F. Screening for Undiagnosed Heart Failure: A Viewpoint. J Card Fail. 2025 Aug;31(8):1339-1344. doi: 10.1016/j.cardfail.2025.04.016. Epub 2025 May 23.", "pmid": "40414280", "type": "DERIVED" }, { "citation": "Pabon MA, Vardeny O, Vaduganathan M, Desai AS, Claggett BL, Kulac IJ, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Saldarriaga CI, Petrie MC, Merkely B, Borentain M, Mueller K, Viswanathan P, Amarante F, Morris A, McMurray JJV, Solomon SD. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):740-745. doi: 10.1001/jamacardio.2025.1101.", "pmid": "40397470", "type": "DERIVED" }, { "citation": "Chimura M, Yang M, Henderson AD, Jhund PS, Docherty KF, Claggett BL, Desai AS, Filippatos G, Gajos G, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Lam CSP, Sato N, Senni M, Voors AA, Zannad F, Yilmaz MB, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Nov;27(11):2301-2312. doi: 10.1002/ejhf.3682. Epub 2025 May 16.", "pmid": "40377177", "type": "DERIVED" }, { "citation": "Kondo T, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Schloemer P, Viswanathan P, Amarante F, Chiang CE, Filippatos G, Lam CSP, Petrie MC, Senni M, Schou M, Verma S, Voors AA, von Lewinski D, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF. Eur J Heart Fail. 2025 Aug;27(8):1459-1471. doi: 10.1002/ejhf.3669. Epub 2025 Apr 29.", "pmid": "40300840", "type": "DERIVED" }, { "citation": "Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Rohwedder K, Lay-Flurrie J, Lavagnino MA, McMurray JJV, Solomon SD. Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102440. doi: 10.1016/j.jchf.2025.03.007. Epub 2025 Apr 2.", "pmid": "40232214", "type": "DERIVED" }, { "citation": "Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025 Aug;27(8):1444-1458. doi: 10.1002/ejhf.3661. Epub 2025 Apr 13.", "pmid": "40222820", "type": "DERIVED" }, { "citation": "Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Schloemer P, Brinker M, Scheerer MF, McMurray JJV, Solomon SD, Vaduganathan M. Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026 Jan;14(1):102439. doi: 10.1016/j.jchf.2025.03.006. Epub 2025 Apr 2.", "pmid": "40208137", "type": "DERIVED" }, { "citation": "Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):678-685. doi: 10.1001/jamacardio.2025.0860.", "pmid": "40159247", "type": "DERIVED" }, { "citation": "Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jul 1;10(7):696-707. doi: 10.1001/jamacardio.2025.0848.", "pmid": "40156827", "type": "DERIVED" }, { "citation": "McDowell K, Docherty KF, Campbell RT, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Hofmeister L, Scalise A, Lam CSP, Petrie MC, Schou M, Senni M, Shah SJ, Udell JA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2025 Jun 1;10(6):535-544. doi: 10.1001/jamacardio.2025.0025.", "pmid": "40042880", "type": "DERIVED" }, { "citation": "Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperon G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD. Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 26;10(4):370-8. doi: 10.1001/jamacardio.2025.0016. Online ahead of print.", "pmid": "40009358", "type": "DERIVED" }, { "citation": "Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Viswanathan P, Kolkhof P, Schloemer P, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV; FINEARTS-HF Committees and Investigators. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 2025 Feb;13(2):107-118. doi: 10.1016/S2213-8587(24)00309-7. Epub 2025 Jan 13.", "pmid": "39818225", "type": "DERIVED" }, { "citation": "Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Lay-Flurrie J, Viswanathan P, Lage A, Scheerer MF, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Kosiborod MN, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2025 Jan 21;85(2):140-155. doi: 10.1016/j.jacc.2024.10.111. Epub 2024 Dec 10.", "pmid": "39665701", "type": "DERIVED" }, { "citation": "Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Jan 1;10(1):59-70. doi: 10.1001/jamacardio.2024.4613.", "pmid": "39550721", "type": "DERIVED" }, { "citation": "Vardeny O, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Matsumoto S, Merkely B, Zieroth S, Yilmaz MB, Lay-Flurrie J, Viswanathan P, Horvat-Broecker A, Scalise A, McMurray JJV, Solomon SD. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025 Jan 1;10(1):42-48. doi: 10.1001/jamacardio.2024.4539.", "pmid": "39550716", "type": "DERIVED" }, { "citation": "Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, Henderson AD, Brinker M, Perkins R, Scheerer MF, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091. Epub 2024 Oct 25.", "pmid": "39490700", "type": "DERIVED" }, { "citation": "Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, Viswanathan P, Scalise A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation. 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATIONAHA.124.072011. Epub 2024 Sep 29.", "pmid": "39342512", "type": "DERIVED" }, { "citation": "Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, Desai AS, Jhund PS, Henderson AD, Brinker M, Lay-Flurrie J, Viswanathan P, Scheerer MF, Lage A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2025 Jan 14;151(2):149-158. doi: 10.1161/CIRCULATIONAHA.124.072055. Epub 2024 Sep 28.", "pmid": "39340828", "type": "DERIVED" }, { "citation": "Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Feb 1;10(2):176-181. doi: 10.1001/jamacardio.2024.3782.", "pmid": "39332395", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2020-09-14", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%" }, { "completion_date": "2014-12-08", "conditions": [ "Worsening Chronic Heart Failure", "Diabetic Nephropathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT04881994", "enrollment": 27, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2021-07-16", "nct_id": "NCT04881994", "phase": "PHASE1", "primary_outcomes": [ "Area under the concentration versus time curve from zero to infinity (AUC) of finerenone in plasma", "Area under the concentration versus time curve from zero to infinity of unbound finerenone (AUCu) in plasma", "Maximum observed drug concentration (Cmax) of finerenone in plasma", "Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma" ], "registry_references": [ { "citation": "Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):619-628. doi: 10.1007/s13318-019-00547-x.", "pmid": "30825073", "type": "RESULT" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2014-03-25", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution" }, { "completion_date": "2012-01-27", "conditions": [ "Worsening Chronic Heart Failure", "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT04908436", "enrollment": 33, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2022-01-28", "nct_id": "NCT04908436", "phase": "PHASE1", "primary_outcomes": [ "Area under the plasma concentration vs time curve from zero to infinity for total (bound and unbound) drug after single dose administration of BAY94-8862 (AUC)", "Maximum total (bound and unbound) drug concentration in plasma after single dose administration of BAY94-8862 (Cmax)", "AUC for unbound drug (AUCu)", "Cmax for unbound drug (Cmax,u)", "AUC divided by dose per kg body weight (AUCnorm)", "AUCnorm for unbound drug (AUCu,norm)", "Cmax divided by dose per body weight (Cmax,norm)", "Cmax,norm for unbound drug (Cmax,u,norm)" ], "registry_references": [ { "citation": "Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. Clin Pharmacol Drug Dev. 2016 Nov;5(6):488-501. doi: 10.1002/cpdd.263. Epub 2016 Jul 18.", "pmid": "27431783", "type": "RESULT" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2010-10-27", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution" }, { "completion_date": "2021-12-31", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05013008", "enrollment": 951, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2023-09-15", "nct_id": "NCT05013008", "phase": "PHASE2", "primary_outcomes": [ "Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2021-08-18", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants" }, { "completion_date": "2026-02-02", "conditions": [ "Non-diabetic Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05047263", "enrollment": 1584, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2026-02-13", "nct_id": "NCT05047263", "phase": "PHASE3", "primary_outcomes": [ "Mean rate of change as measured by the total slope of eGFR from baseline to Month-32." ], "registry_references": [ { "citation": "Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12.", "pmid": "40938666", "type": "DERIVED" }, { "citation": "Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22.", "pmid": "39037799", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2021-09-21", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease" }, { "completion_date": "2027-08-31", "conditions": [ "Chronic Kidney Disease", "Proteinuria" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05196035", "enrollment": 219, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-17", "nct_id": "NCT05196035", "phase": "PHASE3", "primary_outcomes": [ "Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7" ], "registry_references": [ { "citation": "Schaefer F, Montini G, Kang HG, Walle JV, Zaritsky J, Schreuder MF, Litwin M, Scalise A, Scott H, Potts J, Iveli P, Breitenstein S, Warady BA. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials. 2024 Mar 21;25(1):203. doi: 10.1186/s13063-024-08021-z.", "pmid": "38509517", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-03-28", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria" }, { "completion_date": "2025-03-14", "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05254002", "enrollment": 1664, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2025-03-18", "nct_id": "NCT05254002", "phase": "PHASE2", "primary_outcomes": [ "Relative change from baseline in UACR at 180 days in combination therapy group versus empagliflozin alone", "Relative change from baseline in UACR at 180 days in combination therapy group versus finerenone alone", "Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to empagliflozin alone", "Mean ratio of change from baseline to Day 180 in UACR for the combination therapy group, to finerenone alone" ], "registry_references": [ { "citation": "Agarwal R, Correa-Rotter R, Navaneethan SD, Fukami K, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Aldworth C, Green JB, Weir MR. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001071. Online ahead of print.", "pmid": "41905767", "type": "DERIVED" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Solis-Herrera C, Scott C, Li L, Brinker M, Aldworth C, Mann JFE. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. J Am Coll Cardiol. 2026 Feb 24;87(7):772-784. doi: 10.1016/j.jacc.2025.10.049. Epub 2025 Nov 7.", "pmid": "41493296", "type": "DERIVED" }, { "citation": "Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6.", "pmid": "41196655", "type": "DERIVED" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl A, Osonoi T, Pal A, Rossing P, Rosenstock J, Vaduganathan M, Li L, Li N, Scott C, Manjrekar P, Yamashita S, Nangaku M. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE. Clin J Am Soc Nephrol. 2026 Jan 1;21(1):72-82. doi: 10.2215/CJN.0000000865. Epub 2025 Sep 18.", "pmid": "40965042", "type": "DERIVED" }, { "citation": "Vaduganathan M, Green JB, Heerspink HJL, Kim SG, Mann JFE, McGill JB, Mottl A, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Rohwedder K, Scott C, Agarwal R. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant. 2025 Dec 23;41(1):161-170. doi: 10.1093/ndt/gfaf160.", "pmid": "40886054", "type": "DERIVED" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.", "pmid": "40470996", "type": "DERIVED" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022.", "pmid": "39916475", "type": "DERIVED" }, { "citation": "Rossing P. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases. J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5. No abstract available.", "pmid": "39078403", "type": "DERIVED" }, { "citation": "Zachariah T, Radhakrishnan J. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease. Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1499-1512. doi: 10.2215/CJN.0000000000000540. Epub 2024 Jul 22.", "pmid": "39037799", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-06-23", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes" }, { "completion_date": "2026-12-15", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05348733", "enrollment": 4613, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2026-05-11", "nct_id": "NCT05348733", "phase": "Not reported", "primary_outcomes": [ "Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes(T2D).", "Descriptive summary of reasons for introducing finerenone.", "Descriptive summary of reasons for discontinuation of finerenone.", "Planned and actual duration of treatment with finerenone", "Planned and actual daily dose of finerenone treatment", "Planned and actual frequency of finerenone treatment", "Descriptive summary of secondary therapies used in participants with CKD and T2D." ], "registry_references": [ { "citation": "Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6.", "pmid": "41196655", "type": "DERIVED" }, { "citation": "Desai NR, Navaneethan SD, Nicholas SB, Pantalone KM, Wanner C, Hamacher S, Gay A, Wheeler DC. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. J Diabetes Complications. 2023 Apr;37(4):108411. doi: 10.1016/j.jdiacomp.2023.108411. Epub 2023 Feb 2.", "pmid": "36857997", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-06-13", "status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "title": "A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting" }, { "completion_date": "2029-02-27", "conditions": [ "Chronic Kidney Disease", "Proteinuria", "Children" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05457283", "enrollment": 100, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-05-11", "nct_id": "NCT05457283", "phase": "PHASE3", "primary_outcomes": [ "Number of participants with treatment emergent adverse event (TEAEs)", "Change in serum potassium levels from baseline to Day 540\u00b17", "Change in systolic blood pressure (SBP) from baseline to Day 540\u00b17" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-11-08", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria" }, { "completion_date": "2024-09-05", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05526157", "enrollment": 50000, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2024-10-15", "nct_id": "NCT05526157", "phase": "Not reported", "primary_outcomes": [ "Descriptive summary of baseline patient characteristics", "Descriptive summary of patient comorbidities", "Descriptive summary of patient comedications" ], "registry_references": [ { "citation": "Johannes CB, Coleman CI, Kovesdy CP, Khan AM, Ziemiecki R, Layton JB, Vizcaya D, Liu F, Oberprieler NG. Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study. Diabetes Ther. 2026 Feb;17(2):231-250. doi: 10.1007/s13300-025-01825-5. Epub 2025 Dec 9.", "pmid": "41364416", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-10-01", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice" }, { "completion_date": "2025-11-18", "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05552339", "enrollment": 348, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-13", "nct_id": "NCT05552339", "phase": "Not reported", "primary_outcomes": [ "Number of patients with Urine albumin-creatinine ratio (UACR) values between 30 and 299 mg/g and above 300 mg/g" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2023-08-18", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients" }, { "completion_date": "2023-12-20", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05640180", "enrollment": 17847, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2024-01-08", "nct_id": "NCT05640180", "phase": "Not reported", "primary_outcomes": [ "Time to the first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR \u2265 40% from baseline over at least 4 weeks, or renal death", "Time to first occurrence of the composite endpoint of Cardiovascular (CV) death or non-fatal CV event (i.e. myocardial infarction, stroke, or hospitalization for heart failure)" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2022-11-23", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results" }, { "completion_date": "2024-10-01", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05703880", "enrollment": 15948, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2024-10-18", "nct_id": "NCT05703880", "phase": "Not reported", "primary_outcomes": [ "Descriptive summary of characteristics of patients who initiate finerenone and have CKD and T2D in the US.", "Descriptive summary of comorbidities of patients who initiate finerenone and have CKD and T2D in the US.", "Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in the US." ], "registry_references": [ { "citation": "Vizcaya D, Kovesdy CP, Reyes A, Pessina E, Pujol P, James G, Oberprieler NG. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study. J Comp Eff Res. 2023 Aug;12(8):e230076. doi: 10.57264/cer-2023-0076. Epub 2023 Jun 30.", "pmid": "37387399", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2023-06-01", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions" }, { "completion_date": "2025-07-03", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05705271", "enrollment": 200, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2025-07-09", "nct_id": "NCT05705271", "phase": "PHASE4", "primary_outcomes": [ "Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)", "Number of participants with hyperkalemia events" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2023-02-08", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus" }, { "completion_date": "2029-09", "conditions": [ "Acute Kidney Injury" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05806645", "enrollment": 6046, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-07", "nct_id": "NCT05806645", "phase": "NA", "primary_outcomes": [ "Primary effectiveness outcome" ], "registry_references": [], "relevance": "core", "sponsor": "University of Alberta", "sponsor_class": "OTHER", "start_date": "2025-02-12", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "UPTAKE: Using Personalized Risk and Digital Tools to Guide Transitions Following Acute Kidney Events" }, { "completion_date": "2026-07-31", "conditions": [ "Type 2 Diabetes", "Chronic Kidney Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05887817", "enrollment": 100, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2024-02-07", "nct_id": "NCT05887817", "phase": "PHASE4", "primary_outcomes": [ "Change in CAVI" ], "registry_references": [ { "citation": "Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR). Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y.", "pmid": "37525257", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Saga University", "sponsor_class": "OTHER", "start_date": "2023-09-07", "status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)" }, { "completion_date": "2024-09-23", "conditions": [ "Diabetic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05897372", "enrollment": 1, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2024-09-25", "nct_id": "NCT05897372", "phase": "PHASE2", "primary_outcomes": [ "urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline" ], "registry_references": [], "relevance": "core", "sponsor": "Iain Bressendorff", "sponsor_class": "OTHER", "start_date": "2023-08-01", "status": "TERMINATED", "study_type": "INTERVENTIONAL", "title": "Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study" }, { "completion_date": "2025-09-15", "conditions": [ "Chronic Kidney Disease", "Type 1 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05901831", "enrollment": 241, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2025-10-21", "nct_id": "NCT05901831", "phase": "PHASE3", "primary_outcomes": [ "Change in Urinary albumin-to-creatinine ratio (UACR)" ], "registry_references": [ { "citation": "Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Jongs N, Mathieu C, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Brinker M, Scheerer MF, Russell J, Schloemer P, McGill JB; FINE-ONE Investigators. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026 Mar 5;394(10):947-957. doi: 10.1056/NEJMoa2512854.", "pmid": "41780000", "type": "DERIVED" }, { "citation": "Kugathasan L, Aronson Y, Sridhar VS, Ni H, Ouimet JP, Limonte CP, Sarma S, Cherney DZI. Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease. Expert Rev Clin Immunol. 2025 Aug;21(8):1113-1134. doi: 10.1080/1744666X.2025.2537446. Epub 2025 Jul 24.", "pmid": "40693871", "type": "DERIVED" }, { "citation": "Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5.", "pmid": "37805000", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2024-02-26", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes" }, { "completion_date": "2023-09-30", "conditions": [ "Chronic Kidney Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05953701", "enrollment": 800211, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2025-03-19", "nct_id": "NCT05953701", "phase": "Not reported", "primary_outcomes": [ "Percentage of patients with diagnosed CKD", "Percentage of patients with undiagnosed CKD", "Percentage of patients with undiagnosed or diagnosed CKD", "Percentage of patients that fulfil CKD definition according to KDIGO (Kidney Disease: Improving Global Outcomes)" ], "registry_references": [], "relevance": "core", "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "start_date": "2023-07-26", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics" }, { "completion_date": "2023-10-30", "conditions": [ "Heart Failure With Reduced Ejection Fraction", "Diabetes Mellitus", "Diabetic Nephropathies" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05974566", "enrollment": 60, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2023-08-03", "nct_id": "NCT05974566", "phase": "Not reported", "primary_outcomes": [ "Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP)" ], "registry_references": [ { "citation": "Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.", "pmid": "34449181", "type": "RESULT" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "RESULT" }, { "citation": "Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016 Jul 14;37(27):2105-14. doi: 10.1093/eurheartj/ehw132. Epub 2016 Apr 29.", "pmid": "27130705", "type": "RESULT" } ], "relevance": "core", "sponsor": "Chongqing Medical University", "sponsor_class": "OTHER", "start_date": "2023-08-01", "status": "UNKNOWN", "study_type": "OBSERVATIONAL", "title": "Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction" }, { "completion_date": "2027-12", "conditions": [ "Heart Failure", "Acute Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06008197", "enrollment": 5200, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-06", "nct_id": "NCT06008197", "phase": "PHASE3", "primary_outcomes": [ "Composite of total HF events and cardiovascular (CV) death.", "Number of serious adverse events.", "Number of adverse events leading to discontinuation of study drug." ], "registry_references": [], "relevance": "core", "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "start_date": "2024-01-17", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients" }, { "completion_date": "2026-08", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06024746", "enrollment": 1500, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-03-11", "nct_id": "NCT06024746", "phase": "PHASE3", "primary_outcomes": [ "Clinical benefit", "Number of serious adverse events (AEs).", "Number of adverse events leading to discontinuation of study drug." ], "registry_references": [], "relevance": "core", "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "start_date": "2024-07-09", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)" }, { "completion_date": "2028-04", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06033950", "enrollment": 2600, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-03-11", "nct_id": "NCT06033950", "phase": "PHASE3", "primary_outcomes": [ "Time to first occurrence of cardiovascular (CV) death or HF event.", "Number of serious adverse events", "Number of adverse events leading to discontinuation of study drug." ], "registry_references": [], "relevance": "core", "sponsor": "Colorado Prevention Center", "sponsor_class": "OTHER", "start_date": "2024-08-20", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists" }, { "completion_date": "2029-03-31", "conditions": [ "Chronic Kidney Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06058585", "enrollment": 1000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-01", "nct_id": "NCT06058585", "phase": "PHASE3", "primary_outcomes": [ "eGFR slope" ], "registry_references": [ { "citation": "Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998.", "pmid": "39661388", "type": "DERIVED" }, { "citation": "Heerspink HJL, Kretzler M. Clinical Trials for Kidney Disease in the Era of Personalized Medicine. J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9. No abstract available.", "pmid": "39248631", "type": "DERIVED" } ], "relevance": "core", "sponsor": "The George Institute", "sponsor_class": "OTHER", "start_date": "2024-09-04", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect" }, { "completion_date": "2027-12-31", "conditions": [ "Kidney Transplant; Complications" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06059664", "enrollment": 100, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-14", "nct_id": "NCT06059664", "phase": "PHASE2", "primary_outcomes": [ "Feasibility of recruitment to the main clinical trial: Total number of participants who were eligible and enrolled in the main clinical trial", "Feasibility of recruitment to the kidney biopsy substudy: Total number of participants who were eligible and enrolled in the kidney biopsy substudy" ], "registry_references": [ { "citation": "Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725-30. doi: 10.1056/NEJM199912023412303.", "pmid": "10580071", "type": "BACKGROUND" }, { "citation": "Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, Robinson A, Foutz J, Booker SE, Israni AK, Hirose R, Snyder JJ. OPTN/SRTR 2019 Annual Data Report: Kidney. Am J Transplant. 2021 Feb;21 Suppl 2:21-137. doi: 10.1111/ajt.16502.", "pmid": "33595191", "type": "BACKGROUND" }, { "citation": "Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, Yaqub MS, Birdwell KA, Bennett W, Dalal P, Kapoor R, Lerma EV, Lerman M, McCormick N, Bangalore S, McCullough PA, Dadhania DM. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019 May 1;34(5):760-773. doi: 10.1093/ndt/gfz053.", "pmid": "30984976", "type": "BACKGROUND" }, { "citation": "Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RW, Kandaswamy R, Dunn DL, Najarian JS, Sutherland DE. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int. 2002 Aug;62(2):704-14. doi: 10.1046/j.1523-1755.2002.00491.x.", "pmid": "12110036", "type": "BACKGROUND" }, { "citation": "Paraskevas S, Kandaswamy R, Humar A, Gillingham KJ, Gruessner RW, Payne WD, Najarian JS, Sutherland DE, Matas AJ. Risk factors for rising creatinine in renal allografts with 1 and 3 yr survival. Clin Transplant. 2006 Nov-Dec;20(6):667-72. doi: 10.1111/j.1399-0012.2006.00566.x.", "pmid": "17100713", "type": "BACKGROUND" }, { "citation": "Morales JM, Marcen R, del Castillo D, Andres A, Gonzalez-Molina M, Oppenheimer F, Seron D, Gil-Vernet S, Lampreave I, Gainza FJ, Valdes F, Cabello M, Anaya F, Escuin F, Arias M, Pallardo L, Bustamante J. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012 Dec;27 Suppl 4(Suppl 4):iv39-46. doi: 10.1093/ndt/gfs544.", "pmid": "23258810", "type": "BACKGROUND" }, { "citation": "Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004 Feb;4(2):262-9. doi: 10.1046/j.1600-6143.2003.00315.x.", "pmid": "14974949", "type": "BACKGROUND" }, { "citation": "Knoll GA. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis. 2009 Dec;54(6):1131-44. doi: 10.1053/j.ajkd.2009.06.031. Epub 2009 Sep 2.", "pmid": "19726115", "type": "BACKGROUND" }, { "citation": "Lam NN, Tonelli M, Lentine KL, Hemmelgarn B, Ye F, Wen K, Klarenbach S. Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes. Kidney Int. 2017 Aug;92(2):470-478. doi: 10.1016/j.kint.2017.01.028. Epub 2017 Mar 31.", "pmid": "28366228", "type": "BACKGROUND" }, { "citation": "Gaston RS, Fieberg A, Hunsicker L, Kasiske BL, Leduc R, Cosio FG, Gourishankar S, Grande J, Mannon RB, Rush D, Cecka JM, Connett J, Matas AJ. Late graft failure after kidney transplantation as the consequence of late versus early events. Am J Transplant. 2018 May;18(5):1158-1167. doi: 10.1111/ajt.14590. Epub 2017 Dec 5.", "pmid": "29139625", "type": "BACKGROUND" }, { "citation": "Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003 Apr 27;75(8):1291-5. doi: 10.1097/01.TP.0000061602.03327.E2.", "pmid": "12717218", "type": "BACKGROUND" }, { "citation": "Lenihan CR, Liu S, Deswal A, Montez-Rath ME, Winkelmayer WC. De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. Am J Kidney Dis. 2018 Aug;72(2):223-233. doi: 10.1053/j.ajkd.2018.01.041. Epub 2018 Mar 29.", "pmid": "29605378", "type": "BACKGROUND" }, { "citation": "Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, Navaneethan SD, Ramanathan V. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). Am J Nephrol. 2018;48(6):472-481. doi: 10.1159/000495081. Epub 2018 Nov 23.", "pmid": "30472701", "type": "BACKGROUND" }, { "citation": "Gaston RS, Fieberg A, Helgeson ES, Eversull J, Hunsicker L, Kasiske BL, Leduc R, Rush D, Matas AJ; DeKAF Investigators*. Late Graft Loss After Kidney Transplantation: Is \"Death With Function\" Really Death With a Functioning Allograft? Transplantation. 2020 Jul;104(7):1483-1490. doi: 10.1097/TP.0000000000002961.", "pmid": "31568212", "type": "BACKGROUND" }, { "citation": "Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. J Am Soc Nephrol. 2020 Dec;31(12):2887-2899. doi: 10.1681/ASN.2020050566. Epub 2020 Sep 9.", "pmid": "32908001", "type": "BACKGROUND" }, { "citation": "Vinson AJ, Matas A. Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies. J Am Soc Nephrol. 2025 Apr 7;36(8):1659-1667. doi: 10.1681/ASN.0000000726.", "pmid": "40193211", "type": "DERIVED" }, { "citation": "Wajih Z, Karpe KM, Walters GD. Interventions for BK virus infection in kidney transplant recipients. Cochrane Database Syst Rev. 2024 Oct 9;10(10):CD013344. doi: 10.1002/14651858.CD013344.pub2.", "pmid": "39382091", "type": "DERIVED" } ], "relevance": "core", "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "start_date": "2024-04-23", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study" }, { "completion_date": "2029-07-01", "conditions": [ "Cardiovascular Diseases", "Heart Failure", "Type 1 Diabetes", "Kidney Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06082063", "enrollment": 2000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-01-10", "nct_id": "NCT06082063", "phase": "PHASE3", "primary_outcomes": [ "MACE + HHF" ], "registry_references": [ { "citation": "Rossing P. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases. J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5. No abstract available.", "pmid": "39078403", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Steno Diabetes Center Copenhagen", "sponsor_class": "OTHER", "start_date": "2024-07-01", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes" }, { "completion_date": "2025-09-24", "conditions": [ "Diabetes Mellitus Type 2 With Proteinuria", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Diabetes", "Diabetes Complications", "Albuminuria", "Chronic Kidney Diseases", "Chronic Kidney Disease Due to Type 2 Diabetes Mellitus", "Chronic Kidney Disease stage3", "Chronic Kidney Disease stage4", "CKD", "CKD Stage 3", "CKD Stage 4" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06094920", "enrollment": 12, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2026-02-13", "nct_id": "NCT06094920", "phase": "PHASE4", "primary_outcomes": [ "Questionnaire results", "Remote urine collection", "Remote blood pressure measurements", "Remote body weight measurements", "Treatment adherence" ], "registry_references": [], "relevance": "core", "sponsor": "University Medical Center Groningen", "sponsor_class": "OTHER", "start_date": "2024-07-29", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial" }, { "completion_date": "2027-12-01", "conditions": [ "Type 2 Diabetes", "High Blood Pressure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06143566", "enrollment": 200, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-06-17", "nct_id": "NCT06143566", "phase": "PHASE1, PHASE2", "primary_outcomes": [ "Oxygen uptake during peak exercise (Peak VO2)" ], "registry_references": [ { "citation": "Lee MMY, McMurray JJV, Lorenzo-Almoros A, Kristensen SL, Sattar N, Jhund PS, Petrie MC. Diabetic cardiomyopathy. Heart. 2019 Feb;105(4):337-345. doi: 10.1136/heartjnl-2016-310342. Epub 2018 Oct 18. No abstract available.", "pmid": "30337334", "type": "BACKGROUND" }, { "citation": "Segar MW, Vaduganathan M, Patel KV, McGuire DK, Butler J, Fonarow GC, Basit M, Kannan V, Grodin JL, Everett B, Willett D, Berry J, Pandey A. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care. 2019 Dec;42(12):2298-2306. doi: 10.2337/dc19-0587. Epub 2019 Sep 13.", "pmid": "31519694", "type": "BACKGROUND" }, { "citation": "Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13.", "pmid": "34775784", "type": "BACKGROUND" }, { "citation": "Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.", "pmid": "26378978", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "start_date": "2024-03-11", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Polypill for Prevention of Cardiomyopathy" }, { "completion_date": "2025-11-25", "conditions": [ "Type2diabetes" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06244758", "enrollment": 91, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-02", "nct_id": "NCT06244758", "phase": "PHASE3", "primary_outcomes": [ "the impact of finerenone on the oxidative stress level of renal vasculature by the increase of renal perfusion following vitamin C infusion compared to placebo" ], "registry_references": [], "relevance": "core", "sponsor": "University of Erlangen-N\u00fcrnberg Medical School", "sponsor_class": "OTHER", "start_date": "2024-01-18", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Finerenone and Renal Oxidative Stress" }, { "completion_date": "2026-09-30", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06278207", "enrollment": 50000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-03-31", "nct_id": "NCT06278207", "phase": "Not reported", "primary_outcomes": [ "Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone.", "Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone.", "Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone." ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2024-05-15", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions" }, { "completion_date": "2024-12-31", "conditions": [ "Chronic Kidney Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06301022", "enrollment": 90, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2024-03-08", "nct_id": "NCT06301022", "phase": "Not reported", "primary_outcomes": [ "24 hours urinary total protein", "estimate Gromerular filtration rate", "serum potassium" ], "registry_references": [ { "citation": "Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.", "pmid": "33198491", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "First Affiliated Hospital of Harbin Medical University", "sponsor_class": "OTHER", "start_date": "2022-12-15", "status": "UNKNOWN", "study_type": "OBSERVATIONAL", "title": "Effectiveness and Safety of Finerenone in Chinese CKD Patients Without Diabetes Mellitus" }, { "completion_date": "2028-06-30", "conditions": [ "Diabetes Mellitus", "Chronic Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06451458", "enrollment": 20, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-11-24", "nct_id": "NCT06451458", "phase": "NA", "primary_outcomes": [ "HbA1c trajectory", "HbA1c level in control" ], "registry_references": [ { "citation": "Arora S, Kalishman S, Dion D, Som D, Thornton K, Bankhurst A, Boyle J, Harkins M, Moseley K, Murata G, Komaramy M, Katzman J, Colleran K, Deming P, Yutzy S. Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Health Aff (Millwood). 2011 Jun;30(6):1176-84. doi: 10.1377/hlthaff.2011.0278. Epub 2011 May 19.", "pmid": "21596757", "type": "BACKGROUND" }, { "citation": "Arora S, Kalishman SG, Thornton KA, Komaromy MS, Katzman JG, Struminger BB, Rayburn WF, Bradford AM. Project ECHO: A Telementoring Network Model for Continuing Professional Development. J Contin Educ Health Prof. 2017 Fall;37(4):239-244. doi: 10.1097/CEH.0000000000000172.", "pmid": "29189491", "type": "BACKGROUND" }, { "citation": "Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011 Jun 9;364(23):2199-207. doi: 10.1056/NEJMoa1009370. Epub 2011 Jun 1.", "pmid": "21631316", "type": "BACKGROUND" }, { "citation": "MATTHEW F. BOUCHONVILLE, ERIK B. ERHARDT, YURIDIA L. LEYVA, LARISSA MYASKOVSKY, MARK L. UNRUH, SANJEEV ARORA; 1029-P: Building Diabetes Care Capacity in Rural Underserved Communities-A Comparison of Cardiorenal Risk Factor Outcomes in Patients Treated by ECHO-Trained Providers vs. an Academic Medical Center. Diabetes 20 June 2023; 72 (Supplement_1): 1029-P. https://doi.org/10.2337/db23-1029-P", "pmid": "", "type": "BACKGROUND" }, { "citation": "Bouchonville MF, Hager BW, Kirk JB, Qualls CR, Arora S. ENDO ECHO IMPROVES PRIMARY CARE PROVIDER AND COMMUNITY HEALTH WORKER SELF-EFFICACY IN COMPLEX DIABETES MANAGEMENT IN MEDICALLY UNDERSERVED COMMUNITIES. Endocr Pract. 2018 Jan;24(1):40-46. doi: 10.4158/EP-2017-0079.", "pmid": "29368967", "type": "BACKGROUND" }, { "citation": "Bouchonville MF, Paul MM, Billings J, Kirk JB, Arora S. Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model. Curr Diab Rep. 2016 Oct;16(10):96. doi: 10.1007/s11892-016-0784-9.", "pmid": "27549110", "type": "BACKGROUND" }, { "citation": "Nelson RG, Pankratz VS, Ghahate DM, Bobelu J, Faber T, Shah VO. Home-Based Kidney Care, Patient Activation, and Risk Factors for CKD Progression in Zuni Indians: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1801-1809. doi: 10.2215/CJN.06910618. Epub 2018 Nov 15.", "pmid": "30442864", "type": "BACKGROUND" }, { "citation": "Paul M, Davila Saad A, Billings J, Blecker S, Bouchonville MF, Berry C. MON-190 Endo ECHO Improves Patient-Reported Measures of Access to Care, Health Care Quality, Self-Care Behaviors, and Overall Quality of Life for Patients with Complex Diabetes in Medically Underserved Areas of New Mexico. J Endocr Soc. 2019 Apr 30;3(Suppl 1):MON-190. doi: 10.1210/js.2019-MON-190. PMCID: PMC6551170.", "pmid": "", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "start_date": "2024-10-16", "status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "title": "ECHO for Diabetes and Multiple Chronic Conditions Study" }, { "completion_date": "2024-03-31", "conditions": [ "Finerenone", "IgA Nephropathy", "Proteinuria", "Safety Issues" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06460987", "enrollment": 245, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2024-06-14", "nct_id": "NCT06460987", "phase": "Not reported", "primary_outcomes": [ "percentage change in PCR from baseline to 6 months" ], "registry_references": [ { "citation": "Wang QR, Wu L, Huang J, Pan H, Wang XF, Li L, Han F, Wang YF, Wu ML, Yang Y. Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study. Clin Kidney J. 2025 Apr 28;18(5):sfaf125. doi: 10.1093/ckj/sfaf125. eCollection 2025 May.", "pmid": "40357496", "type": "DERIVED" } ], "relevance": "core", "sponsor": "The Fourth Affiliated Hospital of Zhejiang University School of Medicine", "sponsor_class": "OTHER", "start_date": "2022-12-01", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy" }, { "completion_date": "2026-10-30", "conditions": [ "Primary Membranous Nephropathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06573411", "enrollment": 116, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-08", "nct_id": "NCT06573411", "phase": "PHASE4", "primary_outcomes": [ "Relative change in urinary protein content from baseline to 24 weeks." ], "registry_references": [], "relevance": "core", "sponsor": "First Affiliated Hospital, Sun Yat-Sen University", "sponsor_class": "OTHER", "start_date": "2024-09-30", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy" }, { "completion_date": "2026-10-08", "conditions": [ "IgA Nephropathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06580288", "enrollment": 120, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2024-08-30", "nct_id": "NCT06580288", "phase": "PHASE3", "primary_outcomes": [ "change in uACR between the two groups" ], "registry_references": [], "relevance": "core", "sponsor": "Zhejiang University", "sponsor_class": "OTHER", "start_date": "2024-10-08", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Effect of Finerenone in IgA Nephropathy" }, { "completion_date": "2027-12-15", "conditions": [ "Type 2 Diabetes", "Diabetic Cardiomyopathy", "Heart Failure", "Cardiometabolic Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06593327", "enrollment": 300, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-02-27", "nct_id": "NCT06593327", "phase": "NA", "primary_outcomes": [ "Incident Heart Failure or All-cause death" ], "registry_references": [], "relevance": "core", "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "start_date": "2025-02-10", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study" }, { "completion_date": "2026-06-30", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06608212", "enrollment": 150000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-13", "nct_id": "NCT06608212", "phase": "Not reported", "primary_outcomes": [ "Time to the first occurrence of composite cardiovascular outcome" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2024-10-09", "status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "title": "An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States" }, { "completion_date": "2026-12-31", "conditions": [ "Patients With Type 2 Diabetes" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06727409", "enrollment": 82, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2025-03-05", "nct_id": "NCT06727409", "phase": "PHASE4", "primary_outcomes": [ "Change in urine albumin creatinine ratio (uACR)" ], "registry_references": [], "relevance": "core", "sponsor": "Chinese University of Hong Kong", "sponsor_class": "OTHER", "start_date": "2024-12-12", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease" }, { "completion_date": "2026-06-30", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06763146", "enrollment": 1200, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-13", "nct_id": "NCT06763146", "phase": "Not reported", "primary_outcomes": [ "Descriptive summary of specialty of prescribing physician", "Date of finerenone initiation", "If patient was receiving finerenone at the time of each follow-up visit (Yes/No)", "Date of discontinuation of finerenone", "Reason for discontinuation of finerenone", "Dose of finerenone treatment", "Frequency of finerenone treatment", "The number of patients who initiated finerenone with a 10-mg dose and 20-mg dose", "The proportion of patients who initiated finerenone with a 10-mg dose and have up-titrated to a 20-mg dose", "The proportion of patients who initiated finerenone with a 20-mg dose and have down-titrated to a 10-mg dose", "Actions taken after finerenone introduction", "Actions taken after stop finerenone prescription" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2025-09-22", "status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "title": "An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice" }, { "completion_date": "2025-10-01", "conditions": [ "Renal Cell Carcinoma (Kidney Cancer)", "Renal Cell Carcinoma (RCC)", "Nephrectomy", "Chronic Kidney Disease(CKD)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06818305", "enrollment": 10, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2025-12-11", "nct_id": "NCT06818305", "phase": "PHASE2", "primary_outcomes": [ "The incidence of CKD stage 3b (eGFR < 45 mL/min/1.73m\u00b2) at 1 year post-surgery" ], "registry_references": [], "relevance": "core", "sponsor": "Jinling Hospital, China", "sponsor_class": "OTHER", "start_date": "2025-01-01", "status": "TERMINATED", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT" }, { "completion_date": "2026-12-31", "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Disease", "Renal Function" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06838416", "enrollment": 300, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2025-04-04", "nct_id": "NCT06838416", "phase": "Not reported", "primary_outcomes": [ "Change in Urine Albumin-to-Creatinine Ratio (UACR)" ], "registry_references": [], "relevance": "core", "sponsor": "Second Affiliated Hospital of Soochow University", "sponsor_class": "OTHER", "start_date": "2023-11-17", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease" }, { "completion_date": "2028-01", "conditions": [ "Cardiovascular Autonomic Neuropathy", "Type 2 Diabetes", "Diabetic Neuropathies" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06906081", "enrollment": 100, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-05-25", "nct_id": "NCT06906081", "phase": "PHASE2", "primary_outcomes": [ "Between-group (finerenone vs. placebo) difference in changes on the CART E/I ratio" ], "registry_references": [ { "citation": "Bitsch Poulsen M, Okdahl T, Buciek JH, Drewes AM, Karlsson P, Ahluwalia TS, Brock B, Brock C, Rossing P, Hansen CS. Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes. BMJ Open. 2025 Oct 23;15(10):e101074. doi: 10.1136/bmjopen-2025-101074.", "pmid": "41130701", "type": "DERIVED" } ], "relevance": "core", "sponsor": "Peter Rossing", "sponsor_class": "OTHER", "start_date": "2025-05-02", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study" }, { "completion_date": "2027-05-31", "conditions": [ "Type 2 DM", "Type 2 DM /Diabetic Nephropathy", "Albuminuria" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06954090", "enrollment": 50, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2025-12-22", "nct_id": "NCT06954090", "phase": "PHASE4", "primary_outcomes": [ "Proteomic feasibility", "Evaluation of medical treatment" ], "registry_references": [], "relevance": "core", "sponsor": "Steno Diabetes Center Copenhagen", "sponsor_class": "OTHER", "start_date": "2025-11-20", "status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "title": "Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study" }, { "completion_date": "2028-04-30", "conditions": [ "Type 2 Diabetes Mellitus (T2DM)", "Chronic Kidney Disease Due to Type 2 Diabetes Mellitus", "Cardiovascular Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07026539", "enrollment": 80, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-06-24", "nct_id": "NCT07026539", "phase": "PHASE4", "primary_outcomes": [ "Change in left ventricular mass measured by non-contrast cardiac MRI of the heart", "Change in albuminuria measured by a urinary albumin-to-creatinine ratio (UACR) in morning spot urine samples (first morning voids)." ], "registry_references": [], "relevance": "core", "sponsor": "University of Aarhus", "sponsor_class": "OTHER", "start_date": "2024-10-23", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes." }, { "completion_date": "2026-05-21", "conditions": [ "IgA Nephropathy (IgAN)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07056595", "enrollment": 30, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2025-07-09", "nct_id": "NCT07056595", "phase": "NA", "primary_outcomes": [ "Median change in albuminuria from baseline" ], "registry_references": [], "relevance": "core", "sponsor": "Botkin Hospital", "sponsor_class": "OTHER", "start_date": "2025-05-21", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial" }, { "completion_date": "2023-07-28", "conditions": [ "Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent", "Healthy Volunteers" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07116512", "enrollment": 60, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2025-08-11", "nct_id": "NCT07116512", "phase": "PHASE1", "primary_outcomes": [ "Cmax for plasma finerenone concentration", "AUC(0-tlast) for plasma finerenone concentration" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2023-05-02", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants" }, { "completion_date": "2026-02-28", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07124039", "enrollment": 6537, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-14", "nct_id": "NCT07124039", "phase": "Not reported", "primary_outcomes": [ "Descriptive summary of characteristics of patients who initiate finerenone and have CKD and T2D in China.", "Descriptive summary of comorbidities of patients who initiate finerenone and have CKD and T2D in China.", "Descriptive summary of comedications of patients who initiate finerenone and have CKD and T2D in China." ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2025-07-16", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population." }, { "completion_date": "2027-08", "conditions": [ "Diabetic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07155694", "enrollment": 30, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-09-04", "nct_id": "NCT07155694", "phase": "PHASE4", "primary_outcomes": [ "Urine Exosome Assay" ], "registry_references": [], "relevance": "core", "sponsor": "Washington D.C. Veterans Affairs Medical Center", "sponsor_class": "FED", "start_date": "2025-09", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Role of Finerenone in African American Veterans With Diabetic Kidney Disease" }, { "completion_date": "2027-12-31", "conditions": [ "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07181135", "enrollment": 180, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-14", "nct_id": "NCT07181135", "phase": "PHASE3", "primary_outcomes": [ "Urinary albumin-to-creatinine ratio (UACR)" ], "registry_references": [], "relevance": "core", "sponsor": "University Medical Center Groningen", "sponsor_class": "OTHER", "start_date": "2026-03-13", "status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "title": "FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors" }, { "completion_date": "2029-12-30", "conditions": [ "Left Ventricular Systolic Dysfunction", "Heart Failure (Pediatric)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07188805", "enrollment": 111, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-17", "nct_id": "NCT07188805", "phase": "PHASE3", "primary_outcomes": [ "Change in NT-proBNP levels" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2025-11-19", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction" }, { "completion_date": "2030-12-30", "conditions": [ "Left Ventricular Systolic Dysfunction", "Heart Failure (Pediatric)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07192952", "enrollment": 117, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-17", "nct_id": "NCT07192952", "phase": "PHASE3", "primary_outcomes": [ "Number of participants with treatment-emergent adverse events (TEAEs)", "Change in serum potassium levels", "Change in systolic blood pressure (SBP)", "Change in estimated glomerular filtration rate (eGFR)" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2026-06-01", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction" }, { "completion_date": "2028-01-28", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07232537", "enrollment": 500, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-17", "nct_id": "NCT07232537", "phase": "Not reported", "primary_outcomes": [ "Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes (T2D)", "Descriptive summary of reasons for introducing finerenone", "Descriptive summary of reasons for discontinuation of finerenone", "Planned and actual duration of treatment with finerenone", "Planned and actual dosing of finerenone", "Descriptive summary of secondary therapies used in participants with CKD and T2D" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2025-11-20", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea" }, { "completion_date": "2027-03-20", "conditions": [ "Retinal Nerve Fiber Layer Thickness", "Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07235891", "enrollment": 40, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-11-19", "nct_id": "NCT07235891", "phase": "PHASE4", "primary_outcomes": [ "Retinal protection" ], "registry_references": [], "relevance": "core", "sponsor": "Alexandria University", "sponsor_class": "OTHER", "start_date": "2025-11-20", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease" }, { "completion_date": "2028-06", "conditions": [ "Chronic Kidney Disease(CKD)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07239570", "enrollment": 125, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-11-20", "nct_id": "NCT07239570", "phase": "PHASE4", "primary_outcomes": [ "Chronic eGFR slope" ], "registry_references": [], "relevance": "core", "sponsor": "Peter Rossing", "sponsor_class": "OTHER", "start_date": "2025-06-20", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease" }, { "completion_date": "2028-12", "conditions": [ "Type 1 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07270172", "enrollment": 40, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-02-02", "nct_id": "NCT07270172", "phase": "Not reported", "primary_outcomes": [ "Myocardial oxygen consumption", "Renal oxygen consumption" ], "registry_references": [ { "citation": "Stougaard EB, Andersen MR, Bagger JI, Sondergaard E, Ostergaard JA, Curovic VR, Persson F, Almdal T, Mathiesen AS, Andries A, Bohl M, Norgaard LJ, Dejgaard TF, Dorfinger GH, Gustenhoff P, Gaede PH, Hamid YH, Johannesen HL, Juhl CB, Jorgensen ME, Kielgast U, Kofoed-Enevoldsen A, Lindhardt M, Mortensen LS, Thomsen HH, Stidsen J, Sorensen LP, Urhammer S, Rossing P; Steno 1 Study Group. The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study. Diabetes Obes Metab. 2025 Oct;27(10):5432-5443. doi: 10.1111/dom.16606. Epub 2025 Jul 29.", "pmid": "40726451", "type": "RESULT" } ], "relevance": "core", "sponsor": "University of Aarhus", "sponsor_class": "OTHER", "start_date": "2025-10-27", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "The MICRON Study - A Steno 1 Substudy" }, { "completion_date": "2030-12", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07270367", "enrollment": 156, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-12-08", "nct_id": "NCT07270367", "phase": "PHASE3", "primary_outcomes": [ "Left ventricular mass indexed to baseline body surface area (LVMi)" ], "registry_references": [ { "citation": "Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019 Jul 2;8(13):e012272. doi: 10.1161/JAHA.119.012272. Epub 2019 Jun 26.", "pmid": "31240976", "type": "BACKGROUND" }, { "citation": "Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ; EMPA-TROPISM (ATRU-4) Investigators. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. doi: 10.1016/j.jacc.2020.11.008. Epub 2020 Nov 13.", "pmid": "33197559", "type": "BACKGROUND" }, { "citation": "Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007 Dec;48(12):1993-2000. doi: 10.2967/jnumed.107.045427. Epub 2007 Nov 15.", "pmid": "18006623", "type": "BACKGROUND" }, { "citation": "Dorr K, Kammerlander A, Lauriero F, Lorenz M, Marculescu R, Beitzke D. Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial. J Cardiovasc Magn Reson. 2023 Nov 6;25(1):62. doi: 10.1186/s12968-023-00975-4.", "pmid": "37932788", "type": "BACKGROUND" }, { "citation": "Everett RJ, Tastet L, Clavel MA, Chin CWL, Capoulade R, Vassiliou VS, Kwiecinski J, Gomez M, van Beek EJR, White AC, Prasad SK, Larose E, Tuck C, Semple S, Newby DE, Pibarot P, Dweck MR. Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis: A Multicenter Cardiac Magnetic Resonance Study. Circ Cardiovasc Imaging. 2018 Jun;11(6):e007451. doi: 10.1161/CIRCIMAGING.117.007451.", "pmid": "29914867", "type": "BACKGROUND" }, { "citation": "Biederman RW, Magovern JA, Grant SB, Williams RB, Yamrozik JA, Vido DA, Rathi VK, Rayarao G, Caruppannan K, Doyle M. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association. J Cardiothorac Surg. 2011 Apr 14;6:53. doi: 10.1186/1749-8090-6-53.", "pmid": "21492429", "type": "BACKGROUND" }, { "citation": "Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002 Jul 17;40(2):304-10. doi: 10.1016/s0735-1097(02)01965-4.", "pmid": "12106936", "type": "BACKGROUND" }, { "citation": "Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013 Mar;99(5):320-6. doi: 10.1136/heartjnl-2012-303329. Epub 2013 Jan 23.", "pmid": "23343682", "type": "BACKGROUND" }, { "citation": "Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007 Aug 14;50(7):591-6. doi: 10.1016/j.jacc.2007.03.062. Epub 2007 Jul 30.", "pmid": "17692742", "type": "BACKGROUND" }, { "citation": "Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010 Nov 1;106(9):1292-6. doi: 10.1016/j.amjcard.2010.06.052. Epub 2010 Sep 9.", "pmid": "21029826", "type": "BACKGROUND" }, { "citation": "Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Juni P, Zinman B, Connelly KA. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22.", "pmid": "31434508", "type": "BACKGROUND" }, { "citation": "Zhou D, Huang Y, Cai A, Yan M, Cheng Q, Feng X, Nie Z, Feng Y. Longitudinal Study of Left Ventricular Mass Index Trajectories and Risk of Mortality in Hypertension: A Cohort Study. J Am Heart Assoc. 2023 May 2;12(9):e028568. doi: 10.1161/JAHA.122.028568. Epub 2023 Apr 29.", "pmid": "37119065", "type": "BACKGROUND" }, { "citation": "Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, Velazquez EJ, McMurray JJ, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008 Sep;1(5):582-91. doi: 10.1016/j.jcmg.2008.05.012.", "pmid": "19356485", "type": "BACKGROUND" }, { "citation": "Rosch S, Kresoja KP, Besler C, Fengler K, Schober AR, von Roeder M, Lucke C, Gutberlet M, Klingel K, Thiele H, Rommel KP, Lurz P. Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction. Circulation. 2022 Aug 16;146(7):506-518. doi: 10.1161/CIRCULATIONAHA.122.059280. Epub 2022 Jul 8.", "pmid": "35862208", "type": "BACKGROUND" }, { "citation": "Playford D, Strange G, Joseph M, Perry R, Chan YK, Strom JB, Spetko N, Harris SA, Stewart S, Selvanayagam JB. Increasing Left Ventricular Mass and Death in Men and Women Investigated With Echocardiography. J Am Heart Assoc. 2025 Dec 16;14(24):e041927. doi: 10.1161/JAHA.125.041927. Epub 2025 Dec 11.", "pmid": "41378460", "type": "BACKGROUND" }, { "citation": "Maki KC, Wilcox ML, Dicklin MR, Kakkar R, Davidson MH. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2022 Jan 16;23(1):34. doi: 10.1186/s12882-022-02666-1.", "pmid": "35034619", "type": "BACKGROUND" }, { "citation": "Laukkanen JA, Khan H, Kurl S, Willeit P, Karppi J, Ronkainen K, Di Angelantonio E. Left ventricular mass and the risk of sudden cardiac death: a population-based study. J Am Heart Assoc. 2014 Nov 5;3(6):e001285. doi: 10.1161/JAHA.114.001285.", "pmid": "25376188", "type": "BACKGROUND" }, { "citation": "Kawel-Boehm N, Kronmal R, Eng J, Folsom A, Burke G, Carr JJ, Shea S, Lima JAC, Bluemke DA. Left Ventricular Mass at MRI and Long-term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology. 2019 Oct;293(1):107-114. doi: 10.1148/radiol.2019182871. Epub 2019 Aug 27.", "pmid": "31453766", "type": "BACKGROUND" }, { "citation": "Gehlken C, Screever EM, Suthahar N, van der Meer P, Westenbrink BD, Coster JE, Van Veldhuisen DJ, de Boer RA, Meijers WC. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021 Aug;8(4):2458-2466. doi: 10.1002/ehf2.13366. Epub 2021 Jun 4.", "pmid": "34085774", "type": "BACKGROUND" }, { "citation": "Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 Nov 17;292(19):2350-6. doi: 10.1001/jama.292.19.2350.", "pmid": "15547162", "type": "BACKGROUND" }, { "citation": "de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008 Mar;29(6):741-7. doi: 10.1093/eurheartj/ehm605. Epub 2008 Jan 19.", "pmid": "18204091", "type": "BACKGROUND" }, { "citation": "Brown LAE, Wahab A, Ikongo E, Saunderson CED, Jex N, Thirunavukarasu S, Chowdhary A, Das A, Craven TP, Levelt E, Dall'Armellina E, Knott KD, Greenwood JP, Moon JC, Xue H, Kellman P, Plein S, Swoboda PP. Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction. Eur Heart J Cardiovasc Imaging. 2022 Dec 19;24(1):38-45. doi: 10.1093/ehjci/jeac204.", "pmid": "36285884", "type": "BACKGROUND" }, { "citation": "Anstey DE, Tanner RM, Booth JN 3rd, Bress AP, Diaz KM, Sims M, Ogedegbe G, Muntner P, Abdalla M. Inappropriate Left Ventricular Mass and Cardiovascular Disease Events and Mortality in Blacks: The Jackson Heart Study. J Am Heart Assoc. 2019 Aug 20;8(16):e011897. doi: 10.1161/JAHA.118.011897. Epub 2019 Aug 13.", "pmid": "31407619", "type": "BACKGROUND" }, { "citation": "Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011 Oct 18;58(17):1733-40. doi: 10.1016/j.jacc.2011.07.022.", "pmid": "21996383", "type": "BACKGROUND" }, { "citation": "Zhang Y, Zhang X, Wang Y, Hu X, Wang B, Yang J, Zhao X, Zhang L. Relationship between diffuse fibrosis assessed by CMR and depressed myocardial strain in different stages of heart failure. Eur J Radiol. 2023 Jul;164:110848. doi: 10.1016/j.ejrad.2023.110848. Epub 2023 Apr 26.", "pmid": "37156180", "type": "BACKGROUND" }, { "citation": "Schelbert EB, Fridman Y, Wong TC, Abu Daya H, Piehler KM, Kadakkal A, Miller CA, Ugander M, Maanja M, Kellman P, Shah DJ, Abebe KZ, Simon MA, Quarta G, Senni M, Butler J, Diez J, Redfield MM, Gheorghiade M. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. JAMA Cardiol. 2017 Sep 1;2(9):995-1006. doi: 10.1001/jamacardio.2017.2511.", "pmid": "28768311", "type": "BACKGROUND" }, { "citation": "Garg P, Assadi H, Jones R, Chan WB, Metherall P, Thomas R, van der Geest R, Swift AJ, Al-Mohammad A. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep. 2021 Jan 12;11(1):617. doi: 10.1038/s41598-020-79729-6.", "pmid": "33436786", "type": "BACKGROUND" }, { "citation": "von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson. 2016 Jan 22;18:6. doi: 10.1186/s12968-016-0225-6.", "pmid": "26800662", "type": "BACKGROUND" }, { "citation": "Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira VM. Myocardial Tissue Characterization and Fibrosis by Imaging. JACC Cardiovasc Imaging. 2020 May;13(5):1221-1234. doi: 10.1016/j.jcmg.2019.06.030. Epub 2019 Sep 18.", "pmid": "31542534", "type": "BACKGROUND" }, { "citation": "Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89. doi: 10.1186/s12968-016-0308-4.", "pmid": "27899132", "type": "BACKGROUND" }, { "citation": "Gupta S, Ge Y, Singh A, Grani C, Kwong RY. Multimodality Imaging Assessment of Myocardial Fibrosis. JACC Cardiovasc Imaging. 2021 Dec;14(12):2457-2469. doi: 10.1016/j.jcmg.2021.01.027. Epub 2021 May 19.", "pmid": "34023250", "type": "BACKGROUND" }, { "citation": "Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol. 2015 Jan;12(1):18-29. doi: 10.1038/nrcardio.2014.159. Epub 2014 Oct 28.", "pmid": "25348690", "type": "BACKGROUND" }, { "citation": "Ali ND, Behairy N, Kharabish A, Elmozy W, Hegab AY, Saraya S. Cardiac MRI T1 mapping and extracellular volume application in hypertrophic cardiomyopathy. Egypt J Radiol Nucl Med. 2021;52:58.", "pmid": "", "type": "BACKGROUND" }, { "citation": "Unlu S, Ozden O, Celik A. Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View. Card Fail Rev. 2023 Apr 4;9:e04. doi: 10.15420/cfr.2022.27. eCollection 2023.", "pmid": "37387734", "type": "BACKGROUND" }, { "citation": "Rajiah PS, Francois CJ, Leiner T. Cardiac MRI: State of the Art. Radiology. 2023 May;307(3):e223008. doi: 10.1148/radiol.223008. Epub 2023 Apr 11.", "pmid": "37039684", "type": "BACKGROUND" }, { "citation": "Liu C, Ferrari VA, Han Y. Cardiovascular Magnetic Resonance Imaging and Heart Failure. Curr Cardiol Rep. 2021 Mar 8;23(4):35. doi: 10.1007/s11886-021-01464-9.", "pmid": "33686516", "type": "BACKGROUND" }, { "citation": "Han Y, Chen Y, Ferrari VA. Contemporary Application of Cardiovascular Magnetic Resonance Imaging. Annu Rev Med. 2020 Jan 27;71:221-234. doi: 10.1146/annurev-med-041818-015923.", "pmid": "31986088", "type": "BACKGROUND" }, { "citation": "Assadi H, Jones R, Swift AJ, Al-Mohammad A, Garg P. Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: A systematic review and meta-analysis. Magn Reson Imaging. 2021 Feb;76:116-122. doi: 10.1016/j.mri.2020.11.011. Epub 2020 Nov 19.", "pmid": "33221422", "type": "BACKGROUND" }, { "citation": "Smiseth OA, Morris DA, Cardim N, Cikes M, Delgado V, Donal E, Flachskampf FA, Galderisi M, Gerber BL, Gimelli A, Klein AL, Knuuti J, Lancellotti P, Mascherbauer J, Milicic D, Seferovic P, Solomon S, Edvardsen T, Popescu BA; Reviewers: This document was reviewed by members of the 2018-2020 EACVI Scientific Documents Committee. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):e34-e61. doi: 10.1093/ehjci/jeab154.", "pmid": "34729586", "type": "BACKGROUND" }, { "citation": "Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int. 2000 Apr;57(4):1346-51. doi: 10.1046/j.1523-1755.2000.00973.x.", "pmid": "10760065", "type": "BACKGROUND" }, { "citation": "Okoshi MP, Yan X, Okoshi K, Nakayama M, Schuldt AJ, O'Connell TD, Simpson PC, Lorell BH. Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail. 2004 Dec;10(6):511-8. doi: 10.1016/j.cardfail.2004.03.002.", "pmid": "15599842", "type": "BACKGROUND" }, { "citation": "Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992 Dec;120(6):893-901.", "pmid": "1453111", "type": "BACKGROUND" }, { "citation": "Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997 Jun;20(2):85-90. doi: 10.1291/hypres.20.85.", "pmid": "9220271", "type": "BACKGROUND" }, { "citation": "Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002 Jul;40(1):23-7. doi: 10.1161/01.hyp.0000023182.68420.eb.", "pmid": "12105133", "type": "BACKGROUND" }, { "citation": "Buffolo F, Tetti M, Mulatero P, Monticone S. Aldosterone as a Mediator of Cardiovascular Damage. Hypertension. 2022 Sep;79(9):1899-1911. doi: 10.1161/HYPERTENSIONAHA.122.17964. Epub 2022 Jun 29.", "pmid": "35766038", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "Subodh Verma", "sponsor_class": "OTHER", "start_date": "2025-12", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone and Cardiac Remodeling" }, { "completion_date": "2029-12-31", "conditions": [ "Chronic Kidney Disease", "Diabetes (DM)", "Heart Disease", "Stroke", "Chronic Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07280325", "enrollment": 9000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-11", "nct_id": "NCT07280325", "phase": "NA", "primary_outcomes": [ "Hospital Readmissions" ], "registry_references": [ { "citation": "Campbell DJ, Tonelli M, Hemmelgarn B, Mitchell C, Tsuyuki R, Ivers N, Campbell T, Pannu R, Verkerke E, Klarenbach S, King-Shier K, Faris P, Exner D, Chaubey V, Manns B; Interdisciplinary Chronic Disease Collaboration. Assessing outcomes of enhanced chronic disease care through patient education and a value-based formulary study (ACCESS)-study protocol for a 2x2 factorial randomized trial. Implement Sci. 2016 Sep 26;11(1):131. doi: 10.1186/s13012-016-0491-6.", "pmid": "27671037", "type": "BACKGROUND" }, { "citation": "\"Statistics Canada Releases New Health of Canadians Report to Summarize the Current State of Health in the Country.\" Statistics Canadaa, 13 Sept. 2023, www.statcan.gc.ca/en/about/smr09/smr09_142. Accessed 13 Sept. 2023.", "pmid": "", "type": "BACKGROUND" }, { "citation": "\"A Canadian Peer-reviewed Journal of Population Health and Health Services Research.\" Statistics Canada, www150.statcan.gc.ca/n1/pub/82-003-x/82-003-x2020010-eng.htm. Accessed 21 Oct. 2020.", "pmid": "", "type": "BACKGROUND" }, { "citation": "Sumithira, G., et al. \"Incidence and prevalence of diabetes in patients with myocardial infarction: A study in a secondary care hospital.\" International Journal of Pharmaceutical Research (09752366) 12.3 (2020).", "pmid": "", "type": "BACKGROUND" }, { "citation": "Canadian Institute for Health Information. Hospital Morbidity Database (HMDB) metadata. Accessed October 28, 2024.", "pmid": "", "type": "BACKGROUND" }, { "citation": "Discharge abstract database metadata. Canadian Institute for Health Information. https://www.cihi.ca/en/dischargeabstract-database-dad-metadata. Published Unknown. Accessed October 17, 2023.", "pmid": "", "type": "BACKGROUND" }, { "citation": "\"TCPS 2 (2018) - Chapter 3: The Consent Process.\" Panel on Research Ethics, ethics.gc.ca/eng/tcps2-eptc2_2018_chapter3-chapitre3.html#7b. Accessed 22 Jan. 2020.", "pmid": "", "type": "BACKGROUND" }, { "citation": "Ye C, Giangregorio L, Holbrook A, Pullenayegum E, Goldsmith CH, Thabane L. Data withdrawal in randomized controlled trials: Defining the problem and proposing solutions: a commentary. Contemp Clin Trials. 2011 May;32(3):318-22. doi: 10.1016/j.cct.2011.01.016. Epub 2011 Feb 4.", "pmid": "21300179", "type": "BACKGROUND" }, { "citation": "Tripepi G, Jager KJ, Dekker FW, Zoccali C. Selection bias and information bias in clinical research. Nephron Clin Pract. 2010;115(2):c94-9. doi: 10.1159/000312871. Epub 2010 Apr 21.", "pmid": "20407272", "type": "BACKGROUND" }, { "citation": "McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014 Mar;67(3):267-77. doi: 10.1016/j.jclinepi.2013.08.015. Epub 2013 Nov 22.", "pmid": "24275499", "type": "BACKGROUND" }, { "citation": "Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022 Oct 29;17(1):75. doi: 10.1186/s13012-022-01245-0.", "pmid": "36309746", "type": "BACKGROUND" }, { "citation": "Eisman AB, Kilbourne AM, Dopp AR, Saldana L, Eisenberg D. Economic evaluation in implementation science: Making the business case for implementation strategies. Psychiatry Res. 2020 Jan;283:112433. doi: 10.1016/j.psychres.2019.06.008. Epub 2019 Jun 7.", "pmid": "31202612", "type": "BACKGROUND" }, { "citation": "Chen W, Qian L, Shi J, Franklin M. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018 Jun 22;18(1):63. doi: 10.1186/s12874-018-0519-5.", "pmid": "29929477", "type": "BACKGROUND" }, { "citation": "Prieto-Merino D, Mulick A, Armstrong C, Hoult H, Fawcett S, Eliasson L, Clifford S. Estimating proportion of days covered (PDC) using real-world online medicine suppliers' datasets. J Pharm Policy Pract. 2021 Dec 29;14(1):113. doi: 10.1186/s40545-021-00385-w.", "pmid": "34965882", "type": "BACKGROUND" }, { "citation": "Jones CL, Jensen JD, Scherr CL, Brown NR, Christy K, Weaver J. The Health Belief Model as an explanatory framework in communication research: exploring parallel, serial, and moderated mediation. Health Commun. 2015;30(6):566-76. doi: 10.1080/10410236.2013.873363. Epub 2014 Jul 10.", "pmid": "25010519", "type": "BACKGROUND" }, { "citation": "Campbell DJT, Tonelli M, Hemmelgarn BR, Faris P, Zhang J, Au F, Tsuyuki RT, Mitchell C, Pannu R, Campbell T, Ivers N, Fletcher J, Exner DV, Manns BJ; Interdisciplinary Chronic Disease Collaboration. Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial. Circulation. 2023 May 16;147(20):1492-1504. doi: 10.1161/CIRCULATIONAHA.123.064189. Epub 2023 Mar 5.", "pmid": "36871212", "type": "BACKGROUND" }, { "citation": "Shojania KG, McDonald KM, Wachter RM, Owens DK, editors. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol. 1: Series Overview and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Aug. Report No.: 04-0051-1. Available from http://www.ncbi.nlm.nih.gov/books/NBK43908/", "pmid": "20734525", "type": "BACKGROUND" }, { "citation": "Campbell DJT, Lee-Krueger RCW, McBrien K, Anderson T, Quan H, Leung AA, Chen G, Lu M, Naugler C, Butalia S. Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada. BMJ Open. 2020 Nov 24;10(11):e038469. doi: 10.1136/bmjopen-2020-038469.", "pmid": "33234627", "type": "BACKGROUND" }, { "citation": "McAlister FA, Laupacis A, Armstrong PW. Finding the right balance between precision medicine and personalized care. CMAJ. 2017 Aug 21;189(33):E1065-E1068. doi: 10.1503/cmaj.170107. No abstract available.", "pmid": "28827437", "type": "BACKGROUND" }, { "citation": "Priesterroth L, Grammes J, Holtz K, Reinwarth A, Kubiak T. Gamification and Behavior Change Techniques in Diabetes Self-Management Apps. J Diabetes Sci Technol. 2019 Sep;13(5):954-958. doi: 10.1177/1932296818822998. Epub 2019 Feb 14.", "pmid": "30762420", "type": "BACKGROUND" }, { "citation": "Drewniak D, Glassel A, Hodel M, Biller-Andorno N. Risks and Benefits of Web-Based Patient Narratives: Systematic Review. J Med Internet Res. 2020 Mar 26;22(3):e15772. doi: 10.2196/15772.", "pmid": "32213468", "type": "BACKGROUND" }, { "citation": "Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JG. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. Eur J Heart Fail. 2011 Sep;13(9):1028-40. doi: 10.1093/eurjhf/hfr039. Epub 2011 Jul 6.", "pmid": "21733889", "type": "BACKGROUND" }, { "citation": "Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ. 2007 May 5;334(7600):942. doi: 10.1136/bmj.39156.536968.55. Epub 2007 Apr 10.", "pmid": "17426062", "type": "BACKGROUND" }, { "citation": "Farahani MA, Mohammadi E, Ahmadi F, Mohammadi N. Factors influencing the patient education: A qualitative research. Iran J Nurs Midwifery Res. 2013 Mar;18(2):133-9.", "pmid": "23983743", "type": "BACKGROUND" }, { "citation": "Morton K, Beauchamp M, Prothero A, Joyce L, Saunders L, Spencer-Bowdage S, Dancy B, Pedlar C. The effectiveness of motivational interviewing for health behaviour change in primary care settings: a systematic review. Health Psychol Rev. 2015;9(2):205-23. doi: 10.1080/17437199.2014.882006. Epub 2014 Feb 12.", "pmid": "26209209", "type": "BACKGROUND" }, { "citation": "Anderson L, Brown JP, Clark AM, Dalal H, Rossau HK, Bridges C, Taylor RS. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD008895. doi: 10.1002/14651858.CD008895.pub3.", "pmid": "28658719", "type": "BACKGROUND" }, { "citation": "Ma C, Zhou W. Predictors of rehospitalization for community-dwelling older adults with chronic heart failure: A structural equation model. J Adv Nurs. 2020 Jun;76(6):1334-1344. doi: 10.1111/jan.14327. Epub 2020 Feb 26.", "pmid": "32056280", "type": "BACKGROUND" }, { "citation": "Ronksley PE, Sanmartin C, Campbell DJ, Weaver RG, Allan GM, McBrien KA, Tonelli M, Manns BJ, Hennessy D, Hemmelgarn BR. Perceived barriers to primary care among western Canadians with chronic conditions. Health Rep. 2014 Apr;25(4):3-10.", "pmid": "24744042", "type": "BACKGROUND" }, { "citation": "Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009 Apr 2;360(14):1418-28. doi: 10.1056/NEJMsa0803563.", "pmid": "19339721", "type": "BACKGROUND" }, { "citation": "McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT; Kidney Early Evaluation Program Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S38-45. doi: 10.1053/j.ajkd.2007.12.017.", "pmid": "18359407", "type": "BACKGROUND" }, { "citation": "Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.", "pmid": "37807924", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "University of Calgary", "sponsor_class": "OTHER", "start_date": "2026-06-01", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Moxie Self-Management and Education Support Program" }, { "completion_date": "2026-07-01", "conditions": [ "Diabetic Kidney Disease (DKD)", "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07326631", "enrollment": 120, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-01-08", "nct_id": "NCT07326631", "phase": "NA", "primary_outcomes": [ "Number of Participants with Renal Function Decline post finerinone therapy", "Number of Participants with Heart Failure (HF) Event post finerinone therapy", "eGFR Measurement", "Number of Participants with Albuminuria", "Number of Participants with Hyperkalaemia post treatment", "Number of Participants with Cardiovascular (CV) Event post treatment with finerinone therapy" ], "registry_references": [], "relevance": "core", "sponsor": "College of Physicians and Surgeons Pakistan", "sponsor_class": "OTHER", "start_date": "2026-01-01", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure" }, { "completion_date": "2026-04-01", "conditions": [ "Diabetic Kidney Disease (DKD)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07348718", "enrollment": 2000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-01-16", "nct_id": "NCT07348718", "phase": "Not reported", "primary_outcomes": [ "Annualized Estimated Glomerular Filtration Rate (eGFR) Slope" ], "registry_references": [], "relevance": "core", "sponsor": "Rubix LS", "sponsor_class": "INDUSTRY", "start_date": "2025-12-15", "status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "title": "Rubix LS Diabetic Kidney Disease (DKD) Registry Study" }, { "completion_date": "2026-07-31", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07351864", "enrollment": 60, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-01-20", "nct_id": "NCT07351864", "phase": "PHASE4", "primary_outcomes": [ "Cardiovascular Mortality and Heart Failure Hospitalization" ], "registry_references": [ { "citation": "Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13.", "pmid": "34775784", "type": "RESULT" }, { "citation": "Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E, Milaras N, Samaras A, Theofilis P, Fragakis N, Tousoulis D, Xanthos T, Giannakoulas G. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Curr Probl Cardiol. 2024 Jul;49(7):102615. doi: 10.1016/j.cpcardiol.2024.102615. Epub 2024 Apr 29.", "pmid": "38692445", "type": "RESULT" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "RESULT" } ], "relevance": "core", "sponsor": "Mansoura University", "sponsor_class": "OTHER", "start_date": "2026-01-18", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone Plus SGLT2 Inhibitors in Heart Failure" }, { "completion_date": "2028-03-31", "conditions": [ "Kidney Transplantation Recipients", "Proteinuria Patients" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07356388", "enrollment": 54, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-01-21", "nct_id": "NCT07356388", "phase": "PHASE3", "primary_outcomes": [ "Urine Albumin-to-Creatinine Ratio", "creatinine" ], "registry_references": [ { "citation": "Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 Jan;18(1):56-70. doi: 10.1038/s41581-021-00490-8. Epub 2021 Oct 21.", "pmid": "34675379", "type": "BACKGROUND" }, { "citation": "Al Dhaybi O, Bakris GL. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:69-76. doi: 10.1111/dom.13983.", "pmid": "32267074", "type": "BACKGROUND" }, { "citation": "Kolkhof P, Joseph A, Kintscher U. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy. Pharmacol Res. 2021 Oct;172:105859. doi: 10.1016/j.phrs.2021.105859. Epub 2021 Aug 28.", "pmid": "34461222", "type": "BACKGROUND" }, { "citation": "Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam CSP, Kolkhof P, Roberts L, Tasto C, Joseph A, Anker SD; FIDELIO-DKD Investigators. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079. Epub 2021 May 17.", "pmid": "34015478", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.", "pmid": "26325557", "type": "BACKGROUND" }, { "citation": "Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.", "pmid": "33198491", "type": "BACKGROUND" }, { "citation": "Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.", "pmid": "34449181", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "kewen Chen,MD", "sponsor_class": "OTHER", "start_date": "2025-01-30", "status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "title": "FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan" }, { "completion_date": "2027-09-30", "conditions": [ "Chronic Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07379840", "enrollment": 300, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-02-03", "nct_id": "NCT07379840", "phase": "Not reported", "primary_outcomes": [ "Number of adverse events (AEs)" ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2025-12-23", "status": "RECRUITING", "study_type": "OBSERVATIONAL", "title": "A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea" }, { "completion_date": "2028-09-30", "conditions": [ "Acute Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07397650", "enrollment": 550, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-02-11", "nct_id": "NCT07397650", "phase": "PHASE4", "primary_outcomes": [ "A hierarchical composite endpoint of death and worsening heart failure" ], "registry_references": [], "relevance": "core", "sponsor": "Juntendo University", "sponsor_class": "OTHER", "start_date": "2026-02", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure" }, { "completion_date": "2029-12", "conditions": [ "Heart Failure and Preserved Ejection Fraction", "Heart Failure", "Heart Failure and Mildly Reduced Ejection Fraction" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07442448", "enrollment": 40, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-03-02", "nct_id": "NCT07442448", "phase": "PHASE4", "primary_outcomes": [ "Change from baseline in Myocardial Extracellular Volume fraction (ECV)" ], "registry_references": [ { "citation": "Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014 Oct;7(10):991-7. doi: 10.1016/j.jcmg.2014.04.022. Epub 2014 Sep 17.", "pmid": "25240451", "type": "BACKGROUND" }, { "citation": "Wu CK, Lee JK, Hsu JC, Su MM, Wu YF, Lin TT, Lan CW, Hwang JJ, Lin LY. Myocardial adipose deposition and the development of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):445-454. doi: 10.1002/ejhf.1617. Epub 2019 Sep 11.", "pmid": "31696627", "type": "BACKGROUND" }, { "citation": "Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.", "pmid": "39225278", "type": "BACKGROUND" }, { "citation": "Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.", "pmid": "34449181", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "Cathay General Hospital", "sponsor_class": "OTHER", "start_date": "2026-04", "status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "title": "Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure" }, { "completion_date": "2029-03-30", "conditions": [ "IgA Nephropathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07481084", "enrollment": 80, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-03-18", "nct_id": "NCT07481084", "phase": "Not reported", "primary_outcomes": [ "Baseline demographic", "Baseline clinical characteristics: Time of IgAN diagnosis", "Baseline clinical characteristics: Baseline MEST-C", "Baseline clinical characteristics: Index Blood Pressure", "Baseline clinical characteristics: Index eGFR", "Baseline clinical characteristics: Index proteinuria", "Baseline clinical characteristics: Index hematuria", "Baseline clinical characteristics: Index serum albumin level", "Baseline clinical characteristics: Index creatinine level", "Baseline clinical characteristics: Number of participants by Index CKD stage", "Baseline clinical characteristics: Number of participants by ESKD status", "Baseline clinical characteristics: History of dialysis and kidney transplant", "Baseline clinical characteristics: Baseline use of corticosteroids or targeted Budesonide for IgAN", "Baseline clinical characteristics: Baseline use of ACEi, ARB and SGLT2i treatments", "Baseline clinical characteristics: Baseline use of ERA, APRIL / APRIL-BAFF therapies, MMF, Hydroxychloroquine, nsMRA , Immunosuppressant", "Baseline clinical characteristics: Number of participants who have participated in a clinical trial" ], "registry_references": [], "relevance": "core", "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "start_date": "2026-05-29", "status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "title": "IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection" }, { "completion_date": "2026-11", "conditions": [ "Heart Failure", "Diabetic Kidney Disease", "Hyperkalemia" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07523867", "enrollment": 60, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-13", "nct_id": "NCT07523867", "phase": "PHASE4", "primary_outcomes": [ "Clinically Relevant Hyperkalemia" ], "registry_references": [], "relevance": "core", "sponsor": "Hospital de Messejana Dr. Carlos Alberto Studart Gomes", "sponsor_class": "OTHER_GOV", "start_date": "2026-04", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study" }, { "completion_date": "2027-07", "conditions": [ "T2DM (Type 2 Diabetes Mellitus)", "CKD - Chronic Kidney Disease" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07537088", "enrollment": 468, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-22", "nct_id": "NCT07537088", "phase": "PHASE4", "primary_outcomes": [ "Urine Albumin-to-Creatinine Ratio\uff08UACR\uff09" ], "registry_references": [], "relevance": "core", "sponsor": "First Affiliated Hospital of Wannan Medical College", "sponsor_class": "OTHER", "start_date": "2026-05", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease" }, { "completion_date": "2029-03-31", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07547878", "enrollment": 64, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-08", "nct_id": "NCT07547878", "phase": "PHASE4", "primary_outcomes": [ "On-study retention rate at 6 months", "Sustained decline in eGFR \u226530%", "Change in UACR" ], "registry_references": [ { "citation": "Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. Epub 2022 Mar 18.", "pmid": "35529086", "type": "BACKGROUND" }, { "citation": "Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011 Apr;26(4):379-85. doi: 10.1007/s11606-010-1511-x. Epub 2010 Sep 19.", "pmid": "20853156", "type": "BACKGROUND" }, { "citation": "Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 2003 Nov;(87):S24-31. doi: 10.1046/j.1523-1755.64.s87.5.x.", "pmid": "14531770", "type": "BACKGROUND" }, { "citation": "Khan MS, Rashid AM, Shafi T, Rangaswami J, Cherney DZI, Butler J. Residual Risk of Adverse Kidney and Cardiovascular Outcomes in Patients with CKD. Clin J Am Soc Nephrol. 2025 Mar 1;20(3):451-454. doi: 10.2215/CJN.0000000588. Epub 2024 Dec 17. No abstract available.", "pmid": "39688924", "type": "BACKGROUND" }, { "citation": "Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.", "pmid": "38785209", "type": "BACKGROUND" }, { "citation": "Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI. Analysis from the EMPA-REG OUTCOME(R) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019 Aug;96(2):489-504. doi: 10.1016/j.kint.2019.02.033. Epub 2019 Mar 21.", "pmid": "31142441", "type": "BACKGROUND" }, { "citation": "Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Gorriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 Dec 21;42(48):4891-4901. doi: 10.1093/eurheartj/ehab497.", "pmid": "34423370", "type": "BACKGROUND" }, { "citation": "Brownell NK, Ziaeian B, Fonarow GC. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Card Fail Rev. 2021 Nov 26;7:e18. doi: 10.15420/cfr.2021.18. eCollection 2021 Mar.", "pmid": "34950508", "type": "BACKGROUND" }, { "citation": "Lin CY, Hammash M, Miller JL, Schrader M, Mudd-Martin G, Biddle MJ, Moser DK. Delay in seeking medical care for worsening heart failure symptoms: predictors and association with cardiac events. Eur J Cardiovasc Nurs. 2021 Jun 29;20(5):454-463. doi: 10.1093/eurjcn/zvaa032.", "pmid": "33580784", "type": "BACKGROUND" }, { "citation": "Adamo M, Pagnesi M, Mebazaa A, Davison B, Edwards C, Tomasoni D, Arrigo M, Barros M, Biegus J, Celutkiene J, Cerlinskaite-Bajore K, Chioncel O, Cohen-Solal A, Damasceno A, Diaz R, Filippatos G, Gayat E, Kimmoun A, Lam CSP, Novosadova M, Pang PS, Ponikowski P, Saidu H, Sliwa K, Takagi K, Ter Maaten JM, Voors A, Cotter G, Metra M. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. Eur Heart J. 2023 Aug 14;44(31):2947-2962. doi: 10.1093/eurheartj/ehad335.", "pmid": "37217188", "type": "BACKGROUND" }, { "citation": "Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2025 May 1;10(5):407-408. doi: 10.1001/jamacardio.2025.0038.", "pmid": "40042835", "type": "BACKGROUND" }, { "citation": "Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, Neal B, Agarwal R, Bakris G, Perkovic V, Solomon SD, Vaduganathan M. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 Feb 6;149(6):450-462. doi: 10.1161/CIRCULATIONAHA.123.067584. Epub 2023 Nov 12.", "pmid": "37952217", "type": "BACKGROUND" }, { "citation": "Khan MS, Lea JP. Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes. BMC Nephrol. 2024 Aug 1;25(1):248. doi: 10.1186/s12882-024-03652-5.", "pmid": "39090593", "type": "BACKGROUND" }, { "citation": "Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.", "pmid": "36148880", "type": "BACKGROUND" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022.", "pmid": "39916475", "type": "BACKGROUND" }, { "citation": "Agarwal R. Defining end-stage renal disease in clinical trials: a framework for adjudication. Nephrol Dial Transplant. 2016 Jun;31(6):864-7. doi: 10.1093/ndt/gfv289. Epub 2015 Aug 11.", "pmid": "26264780", "type": "BACKGROUND" }, { "citation": "Feng XS, Farej R, Dean BB, Xia F, Gaiser A, Kong SX, Elliott J, Lindemann S, Singh R. CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States. Kidney Med. 2021 Nov 3;4(1):100385. doi: 10.1016/j.xkme.2021.09.003. eCollection 2022 Jan.", "pmid": "35072048", "type": "BACKGROUND" }, { "citation": "Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018. No abstract available.", "pmid": "38490803", "type": "BACKGROUND" }, { "citation": "An L, Wang D, Shi X, He Y, Lee Y, Lu J. Differences in prevalence and management of chronic kidney disease among T2DM inpatients at the grassroots in Beijing and Taiyuan: a retrospective study. J Health Popul Nutr. 2023 Jul 5;42(1):61. doi: 10.1186/s41043-023-00406-1.", "pmid": "37408009", "type": "BACKGROUND" }, { "citation": "Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2024 Mar;83(3):277-287. doi: 10.1053/j.ajkd.2023.09.003. Epub 2023 Dec 21.", "pmid": "38142396", "type": "BACKGROUND" }, { "citation": "Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022 Mar;24(3):365-376. doi: 10.1111/dom.14601. Epub 2021 Dec 1.", "pmid": "34779091", "type": "BACKGROUND" }, { "citation": "Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, Jaar B, Mehta R, Raj D, Rincon-Choles H, Saunders M, Schrauben S, Weir M, Wright J, Go AS; CRIC Study Investigators. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. J Am Coll Cardiol. 2019 Jun 4;73(21):2691-2700. doi: 10.1016/j.jacc.2019.02.071.", "pmid": "31146814", "type": "BACKGROUND" }, { "citation": "Bell DSH, McGill JB, Jerkins T. Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes. Diabetes Obes Metab. 2023 Oct;25(10):2795-2804. doi: 10.1111/dom.15181. Epub 2023 Jul 6.", "pmid": "37409564", "type": "BACKGROUND" }, { "citation": "Rivera E, Clark-Cutaia MN, Schrauben SJ, Townsend RR, Lash JP, Hannan M, Jaar BG, Rincon-Choles H, Kansal S, He J, Chen J, Hirschman KB. Treatment Adherence in CKD and Support From Health care Providers: A Qualitative Study. Kidney Med. 2022 Sep 20;4(11):100545. doi: 10.1016/j.xkme.2022.100545. eCollection 2022 Nov.", "pmid": "36339664", "type": "BACKGROUND" }, { "citation": "Celutkiene J, Cerlinskaite-Bajore K, Cotter G, Edwards C, Adamo M, Arrigo M, Barros M, Biegus J, Chioncel O, Cohen-Solal A, Damasceno A, Diaz R, Filippatos G, Gayat E, Kimmoun A, Leopold V, Metra M, Novosadova M, Pagnesi M, Pang PS, Ponikowski P, Saidu H, Sliwa K, Takagi K, Ter Maaten JM, Tomasoni D, Lam CSP, Voors AA, Mebazaa A, Davison B. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. Circ Heart Fail. 2024 Apr;17(4):e011221. doi: 10.1161/CIRCHEARTFAILURE.123.011221. Epub 2024 Mar 6.", "pmid": "38445950", "type": "BACKGROUND" }, { "citation": "Cotter G, Davison B, Metra M, Sliwa K, Voors AA, Addad F, Celutkiene J, Chioncel O, Cohen Solal A, Diaz R, Damasceno A, Duengen HD, Filippatos G, Goncalvesova E, Merai I, Ponikowski P, Privalov D, Sani MU, Takagi K, Shogenov Z, Saidu H, Mebazaa A. Amended STRONG-HF study design. Eur J Heart Fail. 2021 Nov;23(11):1981-1982. doi: 10.1002/ejhf.2348. Epub 2021 Oct 4. No abstract available.", "pmid": "34529313", "type": "BACKGROUND" }, { "citation": "Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail. 2017 Nov;19(11):1401-1409. doi: 10.1002/ejhf.838. Epub 2017 Jun 8.", "pmid": "28597606", "type": "BACKGROUND" }, { "citation": "Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, Lainscak M, Lund LH, Metra M, Mullens W, Rosano G, Slawik J, Wintrich J, Bohm M. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021 Dec;8(6):4444-4453. doi: 10.1002/ehf2.13646. Epub 2021 Oct 16.", "pmid": "34655282", "type": "BACKGROUND" }, { "citation": "Rashid AM, Khan MS, Cherney DZI, Mehta A, Rangaswami J, Shafi T, Butler J. Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes. J Am Soc Nephrol. 2025 Oct 1;36(10):2061-2076. doi: 10.1681/ASN.0000000752. Epub 2025 May 6.", "pmid": "40327845", "type": "BACKGROUND" }, { "citation": "ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023 [published correction appears in Diabetes Care. 2023 May 1;46(5):1106. doi: 10.2337/dc23-er05.] [published correction appears in Diabetes Care. 2023 Sep 01;46(9):1715. doi: 10.2337/dc23-ad08.]. Diabetes Care. 2023;46(Suppl 1):S19-S40. doi:10.2337/dc23-S002. PubMed PMID: 36507649; PMCID: PMC9810477", "pmid": "", "type": "BACKGROUND" }, { "citation": "Rubin NT, Seaquist ER, Eberly L, Kumar A, Mangia S, Oz G, Moheet A. Relationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia. J Endocr Soc. 2022 Aug 1;6(9):bvac107. doi: 10.1210/jendso/bvac107. eCollection 2022 Sep 1.", "pmid": "35935070", "type": "BACKGROUND" }, { "citation": "Karter AJ, Warton EM, Lipska KJ, Ralston JD, Moffet HH, Jackson GG, Huang ES, Miller DR. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med. 2017 Oct 1;177(10):1461-1470. doi: 10.1001/jamainternmed.2017.3844.", "pmid": "28828479", "type": "BACKGROUND" }, { "citation": "US Food and Drug Administration. Pragmatic Risk Score for Severe Hypoglycemic Events. Published October 28, 2021.", "pmid": "", "type": "BACKGROUND" }, { "citation": "Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012 Mar;65(3):301-8. doi: 10.1016/j.jclinepi.2011.07.011. Epub 2011 Dec 9.", "pmid": "22169081", "type": "BACKGROUND" }, { "citation": "Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1.", "pmid": "39218030", "type": "BACKGROUND" }, { "citation": "Fuhrman DY, Bagshaw SM, Goldstein SL, Legrand M, Shaw AD. Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE? Intensive Care Med. 2024 Oct;50(10):1723-1724. doi: 10.1007/s00134-024-07602-5. Epub 2024 Aug 15. No abstract available.", "pmid": "39145789", "type": "BACKGROUND" }, { "citation": "Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong PW. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med. 2008 Mar 24;168(6):657-62. doi: 10.1001/archinternmed.2007.124.", "pmid": "18362259", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "start_date": "2026-04-30", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)" }, { "completion_date": "2029-04-30", "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes Mellitus" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07554469", "enrollment": 500, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": false, "last_update_posted": "2026-04-28", "nct_id": "NCT07554469", "phase": "Not reported", "primary_outcomes": [ "Percentage of patients who show an improvement in the Klinrisk model score after 24 months of treatment with finerenone." ], "registry_references": [], "relevance": "core", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2026-04-30", "status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "title": "An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score" }, { "completion_date": "2029-12-31", "conditions": [ "HFpEF - Heart Failure With Preserved Ejection Fraction", "TAVI(Transcatheter Aortic Valve Implantation)", "Finerenone" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07575672", "enrollment": 2832, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-08", "nct_id": "NCT07575672", "phase": "PHASE3", "primary_outcomes": [ "A composite of all-cause mortality or worsening of heart failure (hospitalization for HF or urgent HF visit), any of the first occurrence during the follow-up." ], "registry_references": [], "relevance": "core", "sponsor": "Second Affiliated Hospital, School of Medicine, Zhejiang University", "sponsor_class": "OTHER", "start_date": "2026-07-01", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure" }, { "completion_date": "2027-12-31", "conditions": [ "Heart Failure" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07583173", "enrollment": 104, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-13", "nct_id": "NCT07583173", "phase": "PHASE4", "primary_outcomes": [ "Change in CMR-measured extracellular volume (ECV) from baseline to Month 6 (\u2206ECV = ECV[post-treatment] - ECV[baseline])" ], "registry_references": [ { "citation": "Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C, Ahmed FZ, Cooper A, Rajavarma Viswesvaraiah, Russell S, McDonagh T, Williamson PR, Miller CA. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med. 2021 Aug;27(8):1477-1482. doi: 10.1038/s41591-021-01452-0. Epub 2021 Aug 12.", "pmid": "34385704", "type": "BACKGROUND" }, { "citation": "Requena-Ibanez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, Atallah-Lajam F, Giannarelli C, Macaluso F, Lala A, Sanz J, Fuster V, Badimon JJ. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021 Aug;9(8):578-589. doi: 10.1016/j.jchf.2021.04.014.", "pmid": "34325888", "type": "BACKGROUND" }, { "citation": "Mason T, Coelho-Filho OR, Verma S, Chowdhury B, Zuo F, Quan A, Thorpe KE, Bonneau C, Teoh H, Gilbert RE, Leiter LA, Juni P, Zinman B, Jerosch-Herold M, Mazer CD, Yan AT, Connelly KA. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC Cardiovasc Imaging. 2021 Jun;14(6):1164-1173. doi: 10.1016/j.jcmg.2020.10.017. Epub 2021 Jan 13.", "pmid": "33454272", "type": "BACKGROUND" }, { "citation": "Droebner K, Pavkovic M, Grundmann M, Hartmann E, Goea L, Nordlohne J, Klar J, Eitner F, Kolkhof P. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis. Am J Nephrol. 2021;52(7):588-601. doi: 10.1159/000518254. Epub 2021 Aug 30.", "pmid": "34515038", "type": "BACKGROUND" }, { "citation": "Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U. Finerenone Reduces Renal RORgammat gammadelta T Cells and Protects against Cardiorenal Damage. Am J Nephrol. 2022;53(7):552-564. doi: 10.1159/000524940. Epub 2022 Jun 8.", "pmid": "35675794", "type": "BACKGROUND" }, { "citation": "Barton AK, Tzolos E, Bing R, Singh T, Weber W, Schwaiger M, Varasteh Z, Slart RHJA, Newby DE, Dweck MR. Emerging molecular imaging targets and tools for myocardial fibrosis detection. Eur Heart J Cardiovasc Imaging. 2023 Feb 17;24(3):261-275. doi: 10.1093/ehjci/jeac242.", "pmid": "36575058", "type": "BACKGROUND" }, { "citation": "Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5.", "pmid": "40470996", "type": "BACKGROUND" }, { "citation": "Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperon G, Mareev V, Martinez FA, Melenovsky V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024 Oct 24;391(16):1475-1485. doi: 10.1056/NEJMoa2407107. Epub 2024 Sep 1.", "pmid": "39225278", "type": "BACKGROUND" }, { "citation": "Vaduganathan M, Claggett BL, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Desai AS, Jhund PS, Viswanathan P, Bomfim Wirtz A, Schloemer P, Lay-Flurrie J, McMurray JJV, Solomon SD. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial. Eur J Heart Fail. 2024 Jun;26(6):1324-1333. doi: 10.1002/ejhf.3253. Epub 2024 May 14.", "pmid": "38742248", "type": "BACKGROUND" } ], "relevance": "core", "sponsor": "China National Center for Cardiovascular Diseases", "sponsor_class": "OTHER_GOV", "start_date": "2026-05-15", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients" }, { "completion_date": "2028-03-31", "conditions": [ "MASLD", "Chronic Kidney Diseases" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07585526", "enrollment": 160, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-05-13", "nct_id": "NCT07585526", "phase": "NA", "primary_outcomes": [ "Incidence of chronic kidney disease (CKD) in patients with MASLD/NAFLD related cirrhosis with clinical ascites at 6 months between both the groups, defined as:" ], "registry_references": [], "relevance": "core", "sponsor": "Institute of Liver and Biliary Sciences, India", "sponsor_class": "OTHER", "start_date": "2026-04-15", "status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease." }, { "completion_date": "2011-05-17", "conditions": [ "Clinical Pharmacology" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01473108", "enrollment": 67, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2022-02-09", "nct_id": "NCT01473108", "phase": "PHASE1", "primary_outcomes": [ "Log10 (10*urinary Na+/K+ ratio) (Parameter for natriuresis)", "AUC (Area under the concentration vs time curve from zero to infinity after single (first) dose for both BAY 94-8862 and eplerenone)", "Cmax (Maximum observed drug concentration in measured matrix after single dose administration for both BAY 94-8862 and eplerenone)" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2010-03-29", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862" }, { "completion_date": "2014-08-07", "conditions": [ "Diabetic Nephropathies" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01874431", "enrollment": 823, "enrollment_type": "ACTUAL", "has_results": true, "is_randomized": true, "last_update_posted": "2021-07-01", "nct_id": "NCT01874431", "phase": "PHASE2", "primary_outcomes": [ "Ratio of UACR at Day 90 to UACR at Baseline" ], "registry_references": [ { "citation": "Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.", "pmid": "26325557", "type": "RESULT" }, { "citation": "Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x.", "pmid": "31583611", "type": "RESULT" }, { "citation": "Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.", "pmid": "33107592", "type": "RESULT" }, { "citation": "Ostrominski JW, Filippatos G, Claggett BL, Miao ZM, Desai AS, Jhund PS, Henderson A, Rohwedder K, Brinker MD, Scalise A, Schloemer P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD, Vaduganathan M. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2026 Feb 1;37(2):312-325. doi: 10.1681/ASN.0000000823. Epub 2025 Sep 12.", "pmid": "40938666", "type": "DERIVED" }, { "citation": "Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 Feb 1;41(2):295-302. doi: 10.1097/HJH.0000000000003330. Epub 2022 Dec 8.", "pmid": "36583355", "type": "DERIVED" }, { "citation": "Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish.", "pmid": "33358451", "type": "DERIVED" } ], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2013-06-12", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy" }, { "completion_date": "2014-11-07", "conditions": [ "Diabetic Nephropathies" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT01968668", "enrollment": 96, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2021-07-16", "nct_id": "NCT01968668", "phase": "PHASE2", "primary_outcomes": [ "Change of urinary albumin-to creatinine ratio" ], "registry_references": [ { "citation": "Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x.", "pmid": "31583611", "type": "DERIVED" } ], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2013-10-28", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)" }, { "completion_date": "2017-03-17", "conditions": [ "Pharmacokinetics" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT02956109", "enrollment": 16, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2017-07-11", "nct_id": "NCT02956109", "phase": "PHASE1", "primary_outcomes": [ "Finerenone area under the plasma concentration vs. time curve (AUC)", "Finerenone maximum plasma concentration (Cmax)", "Appearance of oro-dispersible tablets assessed by questionnaire", "Taste of oro-dispersible tablets assessed by questionnaire", "Texture of oro-dispersible tablets assessed by questionnaire", "Smell of oro-dispersible tablets assessed by questionnaire", "Overall impression of oro-dispersible tablets assessed by questionnaire", "Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2016-11-16", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers" }, { "completion_date": "2017-03-01", "conditions": [ "Pharmacokinetics" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT02957396", "enrollment": 16, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2017-04-24", "nct_id": "NCT02957396", "phase": "PHASE1", "primary_outcomes": [ "Finerenone area under the plasma concentration vs. time curve (AUC)", "Finerenone maximum plasma concentration (Cmax)", "Appearance of oro-dispersible tablets assessed by questionnaire", "Taste of oro-dispersible tablets assessed by questionnaire", "Texture of oro-dispersible tablets assessed by questionnaire", "Smell of oro-dispersible tablets assessed by questionnaire", "Overall impression of oro-dispersible tablets assessed by questionnaire", "Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2016-11-17", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects" }, { "completion_date": "2021-06-25", "conditions": [ "Diabetic Retinopathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT04477707", "enrollment": 206, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2022-06-29", "nct_id": "NCT04477707", "phase": "Not reported", "primary_outcomes": [ "Progression of non-proliferative diabetic retinopathy (NPDR)" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2020-07-23", "status": "COMPLETED", "study_type": "OBSERVATIONAL", "title": "A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)" }, { "completion_date": "2021-06-30", "conditions": [ "Diabetic Retinopathy" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT04795726", "enrollment": 70, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2022-11-02", "nct_id": "NCT04795726", "phase": "NA", "primary_outcomes": [ "Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR)" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "start_date": "2021-03-10", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)" }, { "completion_date": "2026-12-31", "conditions": [ "Hypertension", "Hyperaldosteronaemia" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05688579", "enrollment": 8000, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2023-04-18", "nct_id": "NCT05688579", "phase": "PHASE4", "primary_outcomes": [ "Occurrence of the composite endpoint" ], "registry_references": [ { "citation": "Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011 Jun;57(6):1069-75. doi: 10.1161/HYPERTENSIONAHA.111.169961. Epub 2011 May 2.", "pmid": "21536989", "type": "BACKGROUND" }, { "citation": "Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9.", "pmid": "29129575", "type": "RESULT" }, { "citation": "Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.", "pmid": "26414968", "type": "RESULT" }, { "citation": "Cannone V, Buglioni A, Sangaralingham SJ, Scott C, Bailey KR, Rodeheffer R, Redfield MM, Sarzani R, Burnett JC Jr. Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population. Mayo Clin Proc. 2018 Aug;93(8):980-990. doi: 10.1016/j.mayocp.2018.05.027.", "pmid": "30077215", "type": "RESULT" }, { "citation": "Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR, Yeh HC, Bertoni AG, Effoe VS, Casanova R, Sims M, Wu WC, Wand GS, Correa A, Golden SH. Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study. JACC Heart Fail. 2017 Sep;5(9):642-651. doi: 10.1016/j.jchf.2017.05.012. Epub 2017 Aug 16.", "pmid": "28822744", "type": "RESULT" }, { "citation": "Inoue K, Goldwater D, Allison M, Seeman T, Kestenbaum BR, Watson KE. Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis. Hypertension. 2020 Jul;76(1):113-120. doi: 10.1161/HYPERTENSIONAHA.120.15006. Epub 2020 May 18.", "pmid": "32418495", "type": "RESULT" }, { "citation": "Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G, Chen J. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich). 2014 Sep;16(9):658-63. doi: 10.1111/jch.12374. Epub 2014 Jul 22.", "pmid": "25052724", "type": "RESULT" } ], "relevance": "adjacent", "sponsor": "Nanfang Li", "sponsor_class": "OTHER", "start_date": "2023-04-16", "status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "title": "Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia" }, { "completion_date": "2026-03", "conditions": [ "Primary Aldosteronism", "Hypertension" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05814770", "enrollment": 96, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2023-04-18", "nct_id": "NCT05814770", "phase": "PHASE4", "primary_outcomes": [ "Hypertension remission rate." ], "registry_references": [], "relevance": "adjacent", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "sponsor_class": "OTHER", "start_date": "2023-05", "status": "UNKNOWN", "study_type": "INTERVENTIONAL", "title": "Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism" }, { "completion_date": "2024-03-12", "conditions": [ "Primary Aldosteronism" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05924620", "enrollment": 60, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2024-06-18", "nct_id": "NCT05924620", "phase": "PHASE4", "primary_outcomes": [ "Compare the change of daytime mean systolic blood pressure in the overall cohort between two groups." ], "registry_references": [], "relevance": "adjacent", "sponsor": "Chongqing Medical University", "sponsor_class": "OTHER", "start_date": "2023-06-21", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism" }, { "completion_date": "2029-12-31", "conditions": [ "Primary Aldosteronism", "Resistant Hypertension", "Secondary Hypertension", "Hyperaldosteronism", "Mineralocorticoid Excess", "Hypertension" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT05925569", "enrollment": 12501, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": true, "last_update_posted": "2025-02-07", "nct_id": "NCT05925569", "phase": "NA", "primary_outcomes": [ "Frequency of PA testing orders by provider" ], "registry_references": [ { "citation": "Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary Aldosteronism: State-of-the-Art Review. Am J Hypertens. 2022 Dec 8;35(12):967-988. doi: 10.1093/ajh/hpac079.", "pmid": "35767459", "type": "BACKGROUND" }, { "citation": "Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9.", "pmid": "29129575", "type": "BACKGROUND" }, { "citation": "Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020 Jul 7;173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26.", "pmid": "32449886", "type": "BACKGROUND" }, { "citation": "Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.", "pmid": "26934393", "type": "BACKGROUND" }, { "citation": "Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Ann Intern Med. 2021 Mar;174(3):289-297. doi: 10.7326/M20-4873. Epub 2020 Dec 29.", "pmid": "33370170", "type": "BACKGROUND" }, { "citation": "Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, Carroll B, Landman AB, Emani S, Goldhaber SZ. Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). Eur Heart J. 2020 Mar 7;41(10):1086-1096. doi: 10.1093/eurheartj/ehz385.", "pmid": "31228189", "type": "BACKGROUND" } ], "relevance": "adjacent", "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "start_date": "2024-03-13", "status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "title": "Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension" }, { "completion_date": "2024-12-16", "conditions": [ "Primary Aldosteronism" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06164379", "enrollment": 150, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2023-12-11", "nct_id": "NCT06164379", "phase": "PHASE4", "primary_outcomes": [ "The change of 24-hour ambulatory systolic blood pressure from the baseline level.", "The proportion of patients with normal serum potassium level." ], "registry_references": [], "relevance": "adjacent", "sponsor": "Shanghai Jiao Tong University School of Medicine", "sponsor_class": "OTHER", "start_date": "2023-12-16", "status": "UNKNOWN", "study_type": "INTERVENTIONAL", "title": "Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism" }, { "completion_date": "2025-06-01", "conditions": [ "Primary Aldosteronism", "Finerenone", "Mineralocorticoid Receptor Antagonist" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06381323", "enrollment": 55, "enrollment_type": "ACTUAL", "has_results": false, "is_randomized": false, "last_update_posted": "2025-09-10", "nct_id": "NCT06381323", "phase": "PHASE4", "primary_outcomes": [ "24h systolic BP drop value" ], "registry_references": [ { "citation": "Li P, Yang F, Lou Y, Zhang Z, Du Y, Zhang J, Ren Y, Tong A, Xie Z, Shi B, Liu J, Liu L, Zhu D. Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study. Hypertension. 2026 May;83(5):e26048. doi: 10.1161/HYPERTENSIONAHA.125.26048. Epub 2026 Jan 22.", "pmid": "41568520", "type": "DERIVED" } ], "relevance": "adjacent", "sponsor": "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School", "sponsor_class": "OTHER", "start_date": "2024-03-01", "status": "COMPLETED", "study_type": "INTERVENTIONAL", "title": "The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism" }, { "completion_date": "2026-06-01", "conditions": [ "Primary Aldosteronism" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06457074", "enrollment": 306, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2024-08-30", "nct_id": "NCT06457074", "phase": "PHASE4", "primary_outcomes": [ "Change from baseline in 24-hour SBP" ], "registry_references": [ { "citation": "Rehan M, Raizman JE, Cavalier E, Don-Wauchope AC, Holmes DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem. 2015 Apr;48(6):377-87. doi: 10.1016/j.clinbiochem.2015.01.003. Epub 2015 Jan 22.", "pmid": "25619896", "type": "BACKGROUND" }, { "citation": "Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.", "pmid": "26934393", "type": "BACKGROUND" }, { "citation": "Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. doi: 10.1016/j.mce.2003.10.008.", "pmid": "15134800", "type": "BACKGROUND" }, { "citation": "Vilela LAP, Almeida MQ. Diagnosis and management of primary aldosteronism. Arch Endocrinol Metab. 2017 May-Jun;61(3):305-312. doi: 10.1590/2359-3997000000274.", "pmid": "28699986", "type": "BACKGROUND" }, { "citation": "Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27.", "pmid": "23713082", "type": "BACKGROUND" }, { "citation": "Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 Feb 1;41(2):295-302. doi: 10.1097/HJH.0000000000003330. Epub 2022 Dec 8.", "pmid": "36583355", "type": "BACKGROUND" }, { "citation": "Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossignol P, Rossing P, Pecoits-Filho R, Anker SD, Joseph A, Lawatscheck R, Wilson D, Gebel M, Bakris GL. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb.", "pmid": "36864892", "type": "BACKGROUND" }, { "citation": "Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL; FIDELIO-DKD Investigators. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.", "pmid": "33198491", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.", "pmid": "26325557", "type": "BACKGROUND" }, { "citation": "Song Y, Yang S, He W, Hu J, Cheng Q, Wang Y, Luo T, Ma L, Zhen Q, Zhang S, Mei M, Wang Z, Qing H, Bruemmer D, Peng B, Li Q; Chongqing Primary Aldosteronism Study (CONPASS) Groupdagger. Confirmatory Tests for the Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study. Hypertension. 2018 Jan;71(1):118-124. doi: 10.1161/HYPERTENSIONAHA.117.10197. Epub 2017 Nov 20.", "pmid": "29158354", "type": "BACKGROUND" }, { "citation": "Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, Gordon RD, McWhinney BC, Ungerer JP, Stowasser M. Diagnosis of Primary Aldosteronism by Seated Saline Suppression Test-Variability Between Immunoassay and HPLC-MS/MS. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz150. doi: 10.1210/clinem/dgz150.", "pmid": "31676899", "type": "BACKGROUND" }, { "citation": "Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, Beuschlein F, Rossi GP, Nishikawa T, Morganti A, Seccia TM, Lin YH, Fallo F, Widimsky J. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020 Oct;38(10):1919-1928. doi: 10.1097/HJH.0000000000002510.", "pmid": "32890264", "type": "BACKGROUND" }, { "citation": "Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JT Jr. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. 2019 May;73(5):e35-e66. doi: 10.1161/HYP.0000000000000087.", "pmid": "30827125", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "BACKGROUND" }, { "citation": "Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernandez-Alfonso MS, Halimi JM, Jarai Z, Jelakovic B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.", "pmid": "37345492", "type": "BACKGROUND" } ], "relevance": "adjacent", "sponsor": "Qifu Li", "sponsor_class": "OTHER", "start_date": "2024-06-04", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone for Patients With Primary Aldosteronism (FAIRY)" }, { "completion_date": "2027-12-31", "conditions": [ "HFpEF", "LVDD", "Myocardial Fibrosis" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06655480", "enrollment": 50, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-04-24", "nct_id": "NCT06655480", "phase": "PHASE2", "primary_outcomes": [ "Change in myocardial extracellular volume (MRI)", "Change in 6-minute walking distance (6MWD)", "Change in N-terminal pro b-type natriuretic peptide (NT-proBNP)", "Change in average E/e' ratio and tricuspid regurgitation velocity", "Change in left atrial volume index (LAVi)" ], "registry_references": [], "relevance": "adjacent", "sponsor": "National Medical Research Center for Cardiology, Ministry of Health of Russian Federation", "sponsor_class": "OTHER_GOV", "start_date": "2025-03-18", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF" }, { "completion_date": "2025-09-10", "conditions": [ "Glomerulonephritis" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT06835322", "enrollment": 100, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2025-03-26", "nct_id": "NCT06835322", "phase": "PHASE2", "primary_outcomes": [ "- Change in kidney function", "- Change in proteinuria", "Change in kidney function" ], "registry_references": [ { "citation": "Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.", "pmid": "33264825", "type": "BACKGROUND" }, { "citation": "Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, Pergola P, Joseph A, Lage A, Mentenich N, Scheerer MF, Bakris GL. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 Feb 13;38(2):372-383. doi: 10.1093/ndt/gfac157.", "pmid": "35451488", "type": "BACKGROUND" }, { "citation": "Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019 Aug;96(2):302-319. doi: 10.1016/j.kint.2019.02.030. Epub 2019 Mar 13.", "pmid": "31133455", "type": "BACKGROUND" }, { "citation": "Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, Brix S, Betz IR, Schupp M, Foryst-Ludwig A, Klopfleisch R, Stawowy P, Houtman R, Kolkhof P, Kintscher U. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018 Apr;71(4):599-608. doi: 10.1161/HYPERTENSIONAHA.117.10360. Epub 2018 Feb 5.", "pmid": "29437893", "type": "BACKGROUND" }, { "citation": "Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.", "pmid": "26325557", "type": "BACKGROUND" }, { "citation": "Hou JH, Zhu HX, Zhou ML, Le WB, Zeng CH, Liang SS, Xu F, Liang DD, Shao SJ, Liu Y, Liu ZH. Changes in the Spectrum of Kidney Diseases: An Analysis of 40,759 Biopsy-Proven Cases from 2003 to 2014 in China. Kidney Dis (Basel). 2018 Feb;4(1):10-19. doi: 10.1159/000484717. Epub 2017 Dec 8.", "pmid": "29594138", "type": "BACKGROUND" }, { "citation": "AlYousef A, AlSahow A, AlHelal B, Alqallaf A, Abdallah E, Abdellatif M, Nawar H, Elmahalawy R. Glomerulonephritis Histopathological Pattern Change. BMC Nephrol. 2020 May 18;21(1):186. doi: 10.1186/s12882-020-01836-3.", "pmid": "32423387", "type": "BACKGROUND" } ], "relevance": "adjacent", "sponsor": "Alexandria University", "sponsor_class": "OTHER", "start_date": "2025-02-20", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis" }, { "completion_date": "2026-10", "conditions": [ "Hypertension (HTN)" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07223502", "enrollment": 30, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-03-09", "nct_id": "NCT07223502", "phase": "PHASE3", "primary_outcomes": [ "Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with SBP reduction", "Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with UACR reduction", "Comparing Net Clinical Benefit (NBC) of the FDC to finerenone with Serum K\u207a reduction" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Sarfez Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "start_date": "2025-12-01", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease" }, { "completion_date": "2028-04-30", "conditions": [ "Henoch Sch\u00f6nlein Purpura Nephritis" ], "ctgov_url": "https://clinicaltrials.gov/study/NCT07315191", "enrollment": 116, "enrollment_type": "ESTIMATED", "has_results": false, "is_randomized": true, "last_update_posted": "2026-01-07", "nct_id": "NCT07315191", "phase": "PHASE4", "primary_outcomes": [ "Percentage of Subjects with a Reduction in 24-Hour Urinary Protein Excretion \u226530% from Baseline" ], "registry_references": [], "relevance": "adjacent", "sponsor": "Capital Institute of Pediatrics, China", "sponsor_class": "OTHER", "start_date": "2025-06-13", "status": "RECRUITING", "study_type": "INTERVENTIONAL", "title": "Finerenone Therapy for Pediatric HSPN With Mild Proteinuria" } ], "truthcert": { "algorithm": "sha256", "hmac": null, "note": "Unsigned MVP receipt; set a signing key in a future release for HMAC receipts.", "payload_hash": "ca34602095c40ba620f81909dae5e0b618376c858279a34d62b2494a8b3d8ae9" } }